The storylines故事线
Click a development’s source links to open the original article.点击进展下方的来源链接可打开原文。
National science & technology awards国家科技奖项
5 · 2024-01-02 → 2026-01-06
▾
Won National Science and Technology Progress Award for TCM classical formula research and COVID-19 treatment.因中药经典名方研究和新冠肺炎治疗获得国家科学技术进步奖。
2024-01-02Project 'Traditional Chinese Medicine Treatment and Drug Development for COVID-19' won Beijing Science and Technology Progress Award (Second Class), jointly with Beijing Hospital of Traditional Chinese Medicine and Tianjin University of Traditional Chinese Medicine.“中医药救治新型冠状病毒感染研究与药物研发”项目获北京市科学技术进步奖二等奖，联合首都医科大学附属北京市中医院、天津中医药大学。
2024-06-24Buchang Pharma and its chairman Zhao Tao won the 2023 National Science and Technology Progress Award (Second Class) for the project 'Key Technologies and Applications of Classical Formula Research Model and Discovery of Chinese Medicine Incompatibility Rules'.步长制药及董事长赵涛荣获2023年度国家科学技术进步奖二等奖，项目为“经典方剂类方研究模式与中药配伍禁忌规律性发现的关键技术及应用”。
2024-07-09Project 'Classic Formula Research Model and Key Technology for Discovering TCM Incompatibility Rules' co-completed by Buchang and Chairman Zhao Tao won the 2023 National Science and Technology Progress Award (Second Class).步长制药及董事长赵涛参与完成的“经典方剂类方研究模式与中药配伍禁忌规律性发现的关键技术及应用”项目获2023年度国家科学技术进步奖二等奖。
2024-08-08Buchang Pharma's wholly-owned subsidiary Shaanxi Buchang Pharmaceutical won the first prize of Shaanxi Provincial Science and Technology Progress Award for the project 'Construction and Application of Safety Technology System for Famous and Authentic Medicinal Materials in Shaanxi'.步长制药全资子公司陕西步长制药有限公司参与的《陕西名优道地药材安全保障技术体系建设及推广应用》项目获得陕西省科学技术进步奖一等奖。
2026-01-06The company's project on key technologies of traditional Chinese medicine resources (e.g., Polygonatum, Salvia miltiorrhiza) won a major science and technology award from the Ministry of Education.公司关于黄精、丹参等大宗中药材资源关键技术创新项目获得教育部重大科技奖励。
Drug registration certificates药品注册证书
14 · 2024-01-02 → 2025-10-13
▾
Subsidiaries received NMPA drug registration certificates for various new drugs and generics.子公司获得国家药监局颁发的多种新药及仿制药注册证书。
2024-01-02Subsidiary Shandong Danhong Pharmaceutical received Drug Registration Certificate for Dapoxetine Hydrochloride Tablets, treating premature ejaculation in men aged 18-64.子公司山东丹红制药获得盐酸达泊西汀片药品注册证书，用于治疗18至64岁男性早泄。
2024-01-16Subsidiary Shaanxi Buchang Pharmaceutical received Drug Registration Certificate for Propranolol Hydrochloride Oral Solution, treating proliferating infantile hemangioma requiring systemic therapy.子公司陕西步长制药获得盐酸普萘洛尔口服溶液药品注册证书，用于需要全身治疗的增殖期婴儿血管瘤。
2024-01-19Subsidiary Shaanxi Buchang Gaoxin Pharmaceutical received Drug Registration Certificate for Pramipexole Dihydrochloride Extended-Release Tablets, treating idiopathic Parkinson's disease in adults.子公司陕西步长高新制药获得盐酸普拉克索缓释片药品注册证书，用于治疗成人特发性帕金森病。
2024-05-28Buchang Pharma's wholly-owned subsidiary Shandong Danhong Pharma received NMPA Drug Registration Certificate for Ezetimibe Tablets, indicated for primary hypercholesterolemia as adjunct to diet, alone or with statins.步长制药全资子公司山东丹红制药收到国家药监局核准签发的依折麦布片《药品注册证书》，适应症为原发性高胆固醇血症（可单独或与他汀类联合使用）。
2024-06-07Buchang Pharma's entrusted manufacturer Shandong Danhong Pharmaceutical received NMPA approval for generic ezetimibe tablets (10mg, Category 4, deemed bioequivalent), indicated for primary hypercholesterolemia and homozygous sitosterolemia.步长制药受托生产方山东丹红制药获国家药监局批准生产化药4类品种依折麦布片（10mg），视同通过一致性评价，用于原发性高胆固醇血症等。
2024-08-06Buchang Pharma's wholly-owned subsidiary Tonghua Guhong Pharmaceutical received the Drug Registration Certificate for Caspofungin Acetate for Injection (注射用醋酸卡泊芬净) from the National Medical Products Administration, for treating suspected fungal infections and candidemia in adults and children.步长制药全资子公司通化谷红制药获得国家药监局核准签发的注射用醋酸卡泊芬净药品注册证书，适用于成人和儿童的可疑真菌感染及念珠菌血症治疗。
2024-09-10Subsidiary Tonghua Guhong received Drug Registration Certificate for Fasudil Hydrochloride Injection (for cerebral vasospasm after subarachnoid hemorrhage).子公司通化谷红获得盐酸法舒地尔注射液（用于蛛网膜下腔出血术后脑血管痉挛）药品注册证书。
2024-09-10Subsidiary Shandong Danhong received Drug Registration Certificate for Levetiracetam Extended-Release Tablets (adjunctive therapy for partial-onset seizures in epilepsy patients aged 12+).子公司山东丹红获得左乙拉西坦缓释片（用于12岁及以上癫痫患者部分性发作的加用治疗）药品注册证书。
2024-11-21Wholly-owned subsidiary Shandong Danhong received drug registration certificates for Sitagliptin Phosphate Tablets and Montelukast Sodium Chewable Tablets from NMPA.全资子公司山东丹红获得国家药监局核准签发的磷酸西格列汀片及孟鲁司特钠咀嚼片《药品注册证书》。
2025-05-27Controlling subsidiary Jilin Tiancheng obtained Drug Registration Certificate for Cisatracurium Besylate Injection (chemical drug class 4, for muscle relaxation during surgery), with R&D investment of approx. RMB 11.15 million.控股子公司吉林天成制药获得苯磺顺阿曲库铵注射液（化学药品4类，用于手术肌肉松弛）药品注册证书，研发投入约1,115.22万元。
2025-06-30Controlling subsidiary Jilin Tiancheng obtained drug registration certificate for Lacosamide injection (20ml:0.2g, chemical class 4) for adjunctive treatment of partial-onset seizures in epilepsy patients aged 4+; R&D cost ~12.52 million yuan.控股子公司吉林天成获得拉考沙胺注射液（20ml:0.2g，化药4类）药品注册证书，用于4岁及以上癫痫患者部分性发作的联合治疗；研发费用约1252万元。
2025-07-01Subsidiary Jilin Tiancheng Pharmaceutical received NMPA Drug Registration Certificate for Lacosamide Injection (chemical class 4, 20ml:0.2g) for adjunctive treatment of partial-onset seizures in patients aged 4+; R&D investment approx. 12.5188 million yuan.控股子公司吉林天成制药获得国家药监局拉考沙胺注射液（化药4类，20ml:0.2g）药品注册证书，用于4岁及以上癫痫患者部分性发作的联合治疗；研发投入约1251.88万元。
2025-08-28Wholly-owned subsidiary Shaanxi Buchang Gaoxin received Drug Registration Certificate from NMPA for Oseltamivir Phosphate Capsules, used for treatment of influenza A and B in adults and children aged 1+ and prophylaxis in adults and adolescents aged 13+.全资子公司陕西步长高新获得国家药监局颁发的磷酸奥司他韦胶囊《药品注册证书》，用于成人和1岁及以上儿童甲型和乙型流感的治疗，以及成人和13岁及以上青少年甲型和乙型流感的预防。
2025-10-13Wholly-owned subsidiary Shandong Danhong Pharmaceutical received the Drug Registration Certificate for Ibuprofen Extended-Release Capsules (0.3g, OTC) from the NMPA, for mild-to-moderate pain and fever.全资子公司山东丹红制药收到国家药监局核准签发的布洛芬缓释胶囊（0.3g，非处方药）《药品注册证书》，用于缓解轻至中度疼痛及发热。
Heze plant capacity expansion菏泽工厂产能扩张
3 · 2024-01-15 → 2025-12-15
▾
Added hard capsule production line, pill production line, and various production license amendments at Heze plant.在菏泽工厂新增硬胶囊生产线、丸剂生产线及多项生产许可变更。
2024-01-15Obtained Shandong Medical Products Administration approval to add a hard capsule production line at Heze plant (No. 1818 Zhonghua West Road).获得山东省药监局许可，在菏泽市中华西路1818号增加综合制剂V车间硬胶囊剂生产线。
2025-11-14Buchang Pharma obtained Shandong Medical Products Administration approval to add a pill production line (综合制剂Ⅵ车间) at its Heze plant and extend entrusted production validity for multiple drugs (e.g., desloratadine, montelukast, ibuprofen) until 2028-2030.步长制药获山东省药监局许可，在菏泽厂区新增丸剂生产线，并延续多项受托生产（如地氯雷他定片、孟鲁司特钠咀嚼片、布洛芬缓释胶囊）有效期至2028-2030年。
2025-12-15Company received approval from Shandong Medical Products Administration to change its Drug Manufacturing License: added entrusted production of Ibuprofen Extended-Release Capsules (NDC H20255656) from Shandong Danhong; removed production of Angong Niuhuang Pills from Liaoning Hancao; added entrusted production of Mida Xin Tablets (0.1mg) from Shandong Buchang Shenzhou at Heze site, valid until 2028-09-09 for registration use.公司获山东省药监局批准变更《药品生产许可证》：新增受托生产山东丹红的布洛芬缓释胶囊（国药准字H20255656）；核减受托生产辽宁汉草堂的安宫牛黄丸；新增在菏泽厂区受托生产山东步长神州的咪达那新片（0.1mg），有效期至2028年9月9日，仅限注册申报。
Investment fund & equity adjustments投资基金与股权调整
7 · 2024-01-17 → 2025-12-12
▾
Waiver of preemptive rights, fund size changes, and equity stake adjustments in investment funds and associates.放弃优先认购权、基金规模变更及在投资基金和联营公司中的股权调整。
2024-01-17Waived preemptive right in Yuanhe Puhua fund; fund size unchanged at 4.258 billion yuan, Buchang maintains 50 million yuan stake.放弃元禾璞华基金优先受让权，基金总认缴规模保持42.58亿元不变，步长维持5000万元份额。
2024-11-13Agreed to waive preemptive right in fund Ruiwo Medical; shareholder Shangyou Yijing transfers 15.51 million yuan fund shares to individual An Jingchuan; company's stake remains 15.5457%.放弃对投资基金瑞伏医疗份额的优先受让权，合伙人上犹益憬将1551万元份额转让给安惊川，公司持股比例不变。
2025-02-25The company waived its preemptive right in a fund share transfer where Yuanhe Puhua Limited Partner (a fund the company participates in) transferred unpaid capital commitments of RMB 50 million, 30 million, and 20 million to three parties; total fund size reduced from RMB 4.258 billion to 4.127 billion; the company's stake increased from 1.17% to 1.21%.公司放弃对元禾璞华有限合伙基金份额转让的优先受让权，该基金未实缴出资额5000万元、3000万元、2000万元分别转让给三方；基金总认缴规模由42.58亿元减至41.27亿元；公司份额比例由1.17%升至1.21%。
2025-06-20Company to acquire 8.50% unpaid equity in Buchang Health Industry (Zhejiang) from Haikou Xinyingyang at 0 yuan, raising stake from 82% to 90.50%.公司拟以0元受让海口鑫营氧持有的步长健康产业（浙江）8.50%未实缴股权，持股比例由82%升至90.50%。
2025-07-08Investment fund Hainan Sanya Yuhai reduced capital from 614.5 million yuan to 514.5 million yuan as limited partner Lvye Investment Group withdrew; Buchang Pharma's stake rose from 16.2734% to 19.4363% with unchanged capital contribution.投资基金海南三亚御海减资，出资额由6.145亿元降至5.145亿元，有限合伙人绿叶投资集团退伙；步长制药出资额不变，持股比例由16.2734%升至19.4363%。
2025-10-29Proposed to increase capital in controlled subsidiary Jinan Buchang Shengyuan Medical Devices by RMB 2.7 million (total RMB 3 million from all shareholders pro rata), raising registered capital from RMB 10 million to RMB 13 million.拟向控股子公司济南步长晟源医疗器械增资270万元（全体股东按比例合计增资300万元），注册资本由1000万元增至1300万元。
2025-12-12Company signed an agreement to increase capital in controlled subsidiary Jinan Buchang Shengyuan Medical Devices by RMB 3M (RMB 1/share) proportionally, raising registered capital from RMB 10M to RMB 13M, with Buchang maintaining 90% stake.公司与各方签署增资协议，按现有持股比例对控股子公司济南步长晟源医疗器械增资300万元（1元/股），注册资本由1000万元增至1300万元，步长持股比例保持90%。
Subsidiary governance & restructuring子公司治理与重组
28 · 2024-01-24 → 2026-06-02
▾
Changes in legal representatives, business scope, equity restructuring, and internal asset transfers among subsidiaries.子公司法定代表人、经营范围变更，股权重组及内部资产划转。
2024-01-24Board meeting approved proposal to change legal representative of a controlled subsidiary.董事会审议通过控股子公司法定代表人变更议案。
2024-07-23Subsidiaries Zhejiang Huapai Biomedical and Hangzhou Saihuapai Biotech completed industrial and commercial registration changes due to the renaming of Hangzhou Yuhang Economic Development Zone to Hangzhou Linping Economic Development Zone.控股子公司浙江华派生物医药有限公司及杭州赛华派生物科技有限公司因杭州余杭经济技术开发区更名为杭州临平经济技术开发区，完成工商变更登记。
2024-09-18Controlled subsidiary Zhejiang Tianyuan Bio-Pharma obtained approval from Zhejiang MPA for changes in Quality Responsible Person and Production Responsible Person on its Drug Manufacturing License.控股子公司浙江天元生物药业获浙江省药监局许可变更《药品生产许可证》质量负责人、质量受权人、生产负责人。
2024-10-18Buchang Pharma approved internal restructuring: transfer biopharma assets, business, and personnel from wholly-owned subsidiary Beijing Buchang New Drug R&D to controlled subsidiary Beijing Boyuan Runbu Pharmaceutical R&D, effective Sep 30, 2024.步长制药批准内部重组：将全资子公司北京步长新药研发的生物制药相关资产、业务、人员转移至控股子公司北京博源润步医药研发，基准日2024年9月30日。
2024-11-06Wholly-owned subsidiary Xi'an Buchang Qihang Pharmacy completed business scope change and obtained new business license.全资子公司西安步长启航药房完成经营范围变更并取得新营业执照。
2024-11-22Three subsidiaries (Shandong Danhong, Shandong Buchang Shenzhou, Qionglai Tianyin) changed enterprise type to comply with Foreign Investment Law.三家子公司（山东丹红、山东步长神州、邛崃天银）变更企业类型以符合《外商投资法》。
2024-11-28Wholly-owned subsidiary Beijing Buchang New Drug R&D completed business scope change and obtained new business license; type changed to limited liability (foreign-invested enterprise sole proprietorship).全资子公司北京步长新药研发完成经营范围变更并取得新营业执照，类型变更为有限责任公司（外商投资企业法人独资）。
2024-12-01Wholly-owned subsidiary Beijing Buchang New Drug R&D completed industrial and commercial registration change, with legal representative Yang Chun and registered capital of 20 million yuan.全资子公司北京步长新药研发有限公司完成工商变更登记，法定代表人杨春，注册资本2000万元。
2024-12-16Controlled subsidiary Shaanxi Modern Innovation Traditional Chinese Medicine Research Institute completed industrial and commercial registration with registered capital changed to 20 million yuan.控股子公司陕西现代创新中药研究院有限公司完成工商变更登记，注册资本变更为2000万元。
2025-01-02Subsidiary Qionglai Tianyin Pharmaceutical completed industrial and commercial registration change for enterprise type conversion under Foreign Investment Law.控股子公司邛崃天银制药完成企业类型变更的工商登记。
2025-01-07Wholly-owned subsidiaries Shandong Danhong Pharmaceutical and Shandong Buchang Shenzhou Pharmaceutical completed industrial and commercial registration changes for enterprise type conversion.全资子公司山东丹红制药和山东步长神州制药完成企业类型变更的工商登记。
2025-01-13Controlled subsidiary Buchang Health Industry (Zhejiang) completed business scope change to include health food (pre-packaged) and special medical purpose formula food sales.控股子公司步长健康产业（浙江）完成经营范围变更，新增保健食品（预包装）和特殊医学用途配方食品销售。
2025-02-25Board of directors approved a resolution to change the name and business scope of a wholly-owned subsidiary.董事会审议通过了《关于全资子公司名称及经营范围变更的议案》。
2025-04-09Buchang Pharma's wholly-owned subsidiaries Baoding Tianhao and Shaanxi Buchang changed their business scopes; Shaanxi Buchang added solar power technology services and contract energy management.步长制药全资子公司保定天浩和陕西步长变更经营范围；陕西步长新增太阳能发电技术服务和合同能源管理。
2025-05-26Controlling subsidiary Shandong Buchang Zhongxinkang changed its legal representative from Ma Xiaoteng to Chen Xuebo.控股子公司山东步长众鑫康医药科技有限公司法定代表人由马晓腾变更为陈学波。
2025-06-14Controlling subsidiary Jinan Buchang Shengyuan Medical Devices completed legal representative change to Xu Wei.控股子公司济南步长晟源医疗器械有限公司完成法定代表人变更为徐伟。
2025-06-21Wholly-owned subsidiary Shandong Kang'ai changed business scope to add cosmetics wholesale and retail, expanding beyond drug production.全资子公司山东康爱变更经营范围，新增化妆品批发、零售业务。
2025-07-03Subsidiary Buchang Changyan Bio-tech completed change of registered address; wholly-owned subsidiary Shandong Kang'ai Pharmaceutical completed change of business scope to include pharmaceutical production and cosmetics wholesale.控股子公司步长畅妍生物科技完成住所变更；全资子公司山东康爱制药完成经营范围变更，新增药品生产和化妆品批发。
2025-07-08Subsidiary Shaanxi Xiandai Innovation underwent equity restructuring: Liu Feng transferred 0.50% unpaid equity to Shi Dongpeng at 0 yuan; Shaanxi Buchang Medical Research transferred 30% unpaid equity to Shaanxi Buchang Pharma at 0 yuan; Buchang Pharma's effective control remained at 86.50%.控股子公司陕西现代创新进行股权重组：刘峰以0元转让0.50%未实缴股权给史东鹏；陕西步长医药研究院以0元转让30%未实缴股权给陕西步长制药；步长制药实际持股比例保持86.50%。
2025-09-05Buchang Pharma's board approved a change of legal representative for its controlling subsidiary.步长制药董事会批准控股子公司法定代表人变更。
2025-10-31Controlled subsidiary Shandong Buchang Youpin Medical Technology completed business registration for change of domicile.控股子公司山东步长优品医疗科技完成住所变更的工商登记。
2025-12-12Controlled subsidiaries Shandong Buchang Yaozhuang Biotechnology and Shandong Buchang Dingsheng Pharmaceutical completed industrial registration for legal representative changes: Yaozhuang changed to Chen Gongming, Dingsheng changed to He Tao.控股子公司山东步长药妆生物科技和山东步长鼎晟药业完成工商变更，法定代表人分别变更为陈功铭和何涛。
2026-01-07Controlling subsidiary Shandong Buchang Chuanfang Pharmaceutical completed industrial and commercial registration for legal representative change to Huang Xiaohua.控股子公司山东步长传方药业完成法定代表人变更为黄小华的工商登记。
2026-01-16Wholly-owned subsidiary Shandong Buchang Qihang Pharmaceutical Sales changed its business scope to add 'import and export of goods' and remove 'food internet sales' and 'health food sales'.全资子公司山东步长启航医药销售经营范围变更，新增“货物进出口”，取消“食品互联网销售”和“保健食品销售”。
2026-01-17Controlling subsidiary Shaanxi Modern Innovation Chinese Medicine Research Institute completed equity restructuring: Shaanxi Buchang Pharmaceutical increased its stake from 56.50% to 86.50% via zero-consideration transfers.控股子公司陕西现代创新中药研究院完成股权结构调整，陕西步长制药持股比例由56.50%上升至86.50%（零对价转让）。
2026-04-07Completed deregistration of wholly-owned subsidiary Shaanxi Buchang Pharmaceutical Research Institute (registered capital 8 million yuan, no operations).完成全资子公司陕西步长医药研究院有限公司注销（注册资本800万元，未开展实际经营）。
2026-05-25Wholly-owned subsidiary Buchang Qihang Pharmaceutical Sales expands its business scope to include 'pre-packaged health food sales'.全资子公司山东步长启航医药销售经营范围新增'保健食品（预包装）销售'。
2026-06-02Subsidiary Shandong Buchang Qihang Pharmaceutical Sales completed business scope change, adding Class III medical device operation, disinfection equipment sales, road cargo transport, etc.子公司山东步长启航医药销售有限公司完成经营范围变更，新增第三类医疗器械经营、消毒器械销售、道路货物运输等。
High-tech enterprise certifications高新技术企业认定
4 · 2024-01-25 → 2026-01-05
▾
Subsidiaries re-certified or newly certified as High-Tech Enterprises, entitling them to preferential tax rates.子公司重新或首次被认定为高新技术企业，享受优惠税率。
2024-01-25Subsidiary Shandong Danhong Pharmaceutical re-certified as High-Tech Enterprise, entitled to 15% corporate income tax rate for 2023-2025.子公司山东丹红制药通过高新技术企业重新认定，2023年至2025年按15%税率缴纳企业所得税。
2024-04-01Buchang Pharma's controlling subsidiary Liaoning Aoda Pharmaceutical received the High-Tech Enterprise Certificate, re-certified by Liaoning Provincial Department of Science and Technology, etc.步长制药控股子公司辽宁奥达制药获得辽宁省科技厅等联合颁发的高新技术企业证书，通过重新认定。
2025-01-14Controlled subsidiary Sichuan Luzhou Buchang Biopharmaceutical passed high-tech enterprise certification, entitled to 15% corporate income tax rate for 2024-2026.控股子公司四川泸州步长生物制药通过高新技术企业认定，2024年至2026年享受15%企业所得税优惠税率。
2026-01-05Wholly-owned subsidiary Tonghua Guhong Pharmaceutical passed the re-identification of High-tech Enterprise, entitled to 15% corporate income tax rate for 2025-2027.全资子公司通化谷红制药通过高新技术企业重新认定，2025年至2027年按15%税率缴纳企业所得税。
Financial results & profit warnings财务业绩与盈利预警
21 · 2024-01-30 → 2026-05-14
▾
Reported annual, quarterly results; multiple profit warnings due to医保 restrictions and goodwill impairment.发布年度、季度业绩；因医保限制和商誉减值多次发布盈利预警。
2024-01-302023 annual results forecast: net profit attributable to parent of 276-368 million yuan, turning from loss to profit, mainly due to reduced goodwill impairment of 550-650 million yuan.2023年业绩预告：归母净利润约2.76亿元至3.68亿元，同比扭亏，主要因商誉减值准备减少至约5.5-6.5亿元。
2024-02-02Buchang Pharma expects 2023 net profit of 276-368 million yuan, reversing loss with YoY growth of 118%-124%.步长制药预计2023年净利润2.76亿至3.68亿元，同比扭亏为盈，增长118%-124%。
2024-04-25Buchang Pharma released 2023 annual report: revenue 13.245 billion yuan, down 11.41% YoY; net profit 319 million yuan, turning from loss to profit (vs -1.53 billion yuan in 2022). Proposed cash dividend of 1.26 yuan per 10 shares, total 138 million yuan.步长制药发布2023年年报：营业收入132.45亿元，同比下降11.41%；净利润3.19亿元，同比扭亏为盈（2022年亏损15.30亿元）。拟每10股派发现金红利1.26元，合计1.38亿元。
2024-04-25Buchang Pharma reported Q1 2024 results: revenue 2.641 billion yuan, down 24.88% YoY; net profit 114 million yuan, down 74.96% YoY, due to reduced sales scale and product mix changes.步长制药2024年一季报：营业收入26.41亿元，同比下降24.88%；净利润1.14亿元，同比下降74.96%，主要因销售规模减少及产品结构变化。
2024-07-09Predicted H1 2024 net profit attributable to parent of approximately RMB 186-268 million, down 64.08%-75.07% YoY, due to医保 restrictions, inclusion in key monitoring lists, rising TCM material costs, and reduced government subsidies.预计2024年上半年归母净利润约1.86-2.68亿元，同比下降64.08%-75.07%，原因包括医保受限、纳入重点监控目录、中药材价格上涨及政府补助减少。
2024-08-27Buchang Pharma reported 2024 H1 results: revenue CNY 5.432 billion, down 21.93% YoY; net profit attributable to shareholders CNY 231 million, down 68.98% YoY, due to医保 restrictions, inclusion of some products in key monitoring lists, rising TCM material costs, and reduced government subsidies.步长制药发布2024年半年度报告：营业收入54.32亿元，同比下降21.93%；归属于上市公司股东的净利润2.31亿元，同比下降68.98%，原因包括部分产品医保受限或被纳入重点监控目录、中药材价格上涨及政府补助减少。
2024-10-28Buchang Pharma reported Q3 2024 results: revenue 30.83 billion yuan (+1.89% YoY), net profit 81.45 million yuan (-54.50% YoY); 9-month revenue 85.14 billion yuan (-14.71%), net profit 313 million yuan (-66.18%).步长制药发布2024年三季报：第三季度营收30.83亿元（同比+1.89%），净利润8144.65万元（同比-54.50%）；前三季度营收85.14亿元（同比-14.71%），净利润3.13亿元（同比-66.18%）。
2024-10-28Buchang Pharma attributed the 66.18% net profit decline to医保 restrictions, inclusion of some products in provincial key monitoring lists, rising TCM herb costs, and reduced government subsidies.步长制药将净利润下降66.18%归因于部分产品医保受限或被纳入省级重点监控目录、中药材价格上涨以及政府补助减少。
2024-11-07Q3 2024 report: revenue 8.514 billion yuan (-14.71% YoY); net profit 313 million yuan (-66.18% YoY); gross margin 57.12% (-11.54pp); net margin 2.56% (-5.77pp).2024年三季报：营业收入85.14亿元（同比-14.71%）；归母净利润3.13亿元（同比-66.18%）；毛利率57.12%（-11.54个百分点）；净利率2.56%（-5.77个百分点）。
2025-04-01Buchang Pharma issued a 2024 annual performance forecast, expecting a net loss attributable to parent of RMB 428 million to RMB 808 million, and a non-recurring adjusted net loss of RMB 368 million to RMB 708 million.步长制药发布2024年度业绩预告，预计归属于母公司所有者的净利润亏损4.28亿元至8.08亿元，扣非净利润亏损3.68亿元至7.08亿元。
2025-04-25Buchang Pharma reported Q1 2025 revenue of RMB 27.85 billion, up 5.47% YoY; net profit attributable to parent of RMB 307 million, up 169.49% YoY; operating cash flow of RMB 678 million, up 814.82% YoY. Growth driven by higher drug sales, product mix changes, and end of amortization from acquisition of Tonghua Guhong and Jilin Tiancheng.步长制药2025年一季度营收27.85亿元，同比增长5.47%；归母净利润3.07亿元，同比增长169.49%；经营现金流6.78亿元，同比增长814.82%。增长源于药品销售增加、产品结构变化及收购通化谷红和吉林天成的评估增值摊销完毕。
2025-07-14Released 2025 H1 profit forecast: net profit attributable to parent 488-708 million yuan, up 110.88%-205.94% YoY; non-GAAP net profit 476-702 million yuan, up 115.40%-217.67% YoY; driven by higher drug sales, lower production costs, and end of amortization from past acquisitions.发布2025年半年度业绩预告：归母净利润4.88-7.08亿元，同比增长110.88%-205.94%；扣非净利润4.76-7.02亿元，同比增长115.40%-217.67%；主因药品销售增长、生产成本下降及过往收购摊销完毕。
2025-08-27Released 2025 half-year results: revenue RMB 5.664 billion (+4.27% YoY), net profit attributable to shareholders RMB 628 million (+171.24% YoY), EPS RMB 0.5934, proposed cash dividend of RMB 3.90 per 10 shares.发布2025年半年度报告：营业收入56.64亿元（同比+4.27%），归母净利润6.28亿元（同比+171.24%），基本每股收益0.5934元，拟每10股派发现金红利3.90元。
2025-09-02Buchang Pharma reported 2025 H1 net profit attributable to parent of 628 million yuan (YoY +171.24%), non-GAAP net profit of 619 million yuan (YoY +180.04%), driven by sales growth, lower production costs, and amortization completion of valuation increments from Tonghua Guhong and Jilin Tiancheng acquisitions.步长制药2025年上半年归母净利润6.28亿元（同比+171.24%），扣非归母净利润6.19亿元（同比+180.04%），受销售增长、生产成本下降及通化谷红、吉林天成收购评估增值摊销完毕推动。
2025-10-29Q3 2025 results: revenue RMB 2.805 billion (-9.02% YoY), net profit RMB 241 million (+195.44% YoY). 9M 2025: revenue RMB 8.469 billion (-0.54% YoY), net profit RMB 868 million (+177.54% YoY).2025年第三季度业绩：营收28.05亿元（同比-9.02%），净利润2.41亿元（同比+195.44%）；前三季度营收84.69亿元（同比-0.54%），净利润8.68亿元（同比+177.54%）。
2026-01-27FY2025 preliminary results: net profit attributable to parent 320-468 million yuan (vs loss of 554 million yuan in FY2024), turning profitable;扣非 net profit 590-868 million yuan. Driven by lower goodwill impairment, higher drug sales, lower production costs, and end of amortization of acquisition-related valuation increments.2025年度业绩预告：归母净利润约3.2亿元至4.68亿元（上年同期亏损5.54亿元），实现扭亏为盈；扣非归母净利润约5.9亿元至8.68亿元。主因商誉减值计提减少、药品销售增长、生产成本下降及收购评估增值摊销完毕。
2026-02-26Buchang disclosed 2025 performance forecast showing a fundamental turnaround to profitability, with core operating data stable and improving.步长制药披露2025年业绩预告，实现根本性扭亏，核心经营数据稳健向好。
2026-04-272025 annual results: revenue 11.875 billion yuan (+7.90% YoY); net profit 361 million yuan (vs -554 million yuan loss in 2024, turning profitable). Proposed final dividend 1.80 yuan per 10 shares.2025年年报：营业收入118.75亿元（同比+7.90%）；净利润3.61亿元（2024年亏损5.54亿元，实现扭亏为盈）。拟每10股派发现金红利1.80元。
2026-04-272026 Q1 results: revenue 2.579 billion yuan (-7.39% YoY); net profit 320 million yuan (+4.28% YoY).2026年一季报：营业收入25.79亿元（同比-7.39%）；净利润3.20亿元（同比+4.28%）。
2026-04-272025 annual cash dividend plan: total payout 188.59 million yuan (1.80 yuan per 10 shares). Combined with interim dividend of 411 million yuan, total 2025 cash dividend 600 million yuan, plus share repurchases 98 million yuan, totaling 193.45% of net profit.2025年度末期利润分配方案：合计派发现金红利1.8859亿元（每10股1.80元）。加上中期分红4.11亿元，2025年度现金分红合计6亿元，与股份回购合计占归母净利润193.45%。
2026-05-14Buchang reports 2025 full-year results: revenue up 7.9% YoY to 11.875 billion yuan, net profit turns to 361 million yuan from a loss of 554 million yuan in 2024; 2026 Q1 revenue down 7.39% to 2.579 billion yuan, net profit up 4.28% to 320 million yuan.步长制药披露2025年年报：营收同比增长7.9%至118.75亿元，归母净利润3.61亿元，较2024年净亏损5.54亿元扭亏；2026年一季度营收同比下降7.39%至25.79亿元，净利润同比增长4.28%至3.20亿元。
Strategic cooperation & partnerships战略合作与伙伴关系
5 · 2024-02-02 → 2026-05-09
▾
Strategic cooperation agreements, joint ventures, and R&D service contracts with external parties.与外部方签订战略合作协议、合资及研发服务合同。
2024-02-02Subsidiary Changrui Bio (Chengdu) and Chengdu Guosheng Innovation Tech Services set up JV Chengdu Guosheng Bio with registered capital 50 million yuan; Changrui contributes 7.5 million yuan for 15% stake.子公司长睿生物（成都）与成都国生创新科技服务有限公司共同设立合资公司成都国生生物科技有限公司，注册资本5000万元，长睿生物出资750万元持股15%。
2025-05-20Controlling subsidiary Zhejiang Tianyuan signed an entrusted R&D agreement with Fubicheng (Shanghai) Pharma for MF59 emulsion adjuvant; IND-stage service fee of RMB 1.2 million plus commercial-stage sales royalties.控股子公司浙江天元生物药业与辅必成（上海）医药科技就MF59乳佐剂签署委托研发协议；IND阶段服务费120万元，商业化阶段按年净销售额提成。
2025-10-16Controlled subsidiary Luzhou Buchang signed a Technology Service Contract with WuXi AppTec (Suzhou) for pharmacokinetics and toxicology testing, total contract value RMB 10.8 million (incl. 6% tax).控股子公司泸州步长与苏州药明康德签订《技术服务合同》，委托进行药代动力学和毒理学试验，合同总金额1080万元（含6%税费）。
2025-11-17Buchang Pharma's controlled subsidiary Zhejiang Huapai invested 222,200 yuan (11.11% stake) to jointly establish Nanjing Keyinuo Biotechnology Co., Ltd. with Hefei Keyinuo, Jiangsu Industrial Technology Research Institute, and Hefei Kesaisi.步长制药控股子公司浙江华派出资22.22万元（持股11.11%），与合肥科医诺、江苏省产业技术研究院等共同设立南京科医诺生物科技有限公司。
2026-05-09Sinopharm Holding and Buchang Pharmaceuticals sign a strategic cooperation agreement in Xi'an to deepen all-round collaboration covering channel optimization, innovative drug commercialization, logistics coordination, and full-scenario health services.国药控股与步长制药在西安达成战略签约，深化全方位合作，涵盖渠道优化、创新药商业化、物流协同及全场景健康服务。
Share buyback programs股份回购计划
23 · 2024-02-19 → 2026-06-22
▾
Multiple share buyback programs executed and expanded from 2024 to 2026.2024年至2026年多次执行并扩大股份回购计划。
2024-02-19Buchang Pharma repurchased 5.404 million shares (0.4886% of total) via centralized bidding, total paid 81.16 million yuan, price range 14.16-16.56 yuan/share.步长制药通过集中竞价交易累计回购540.4万股（占总股本0.4886%），支付总额8116.15万元，价格区间14.16-16.56元/股。
2024-03-01Buchang Pharma repurchased 10.4888 million shares (0.9483% of total equity) for 167 million yuan via centralized bidding as of Feb 29, 2024.步长制药截至2024年2月29日通过集中竞价累计回购股份1048.88万股（占总股本0.9483%），支付总金额1.67亿元。
2024-05-06Buchang Pharma disclosed monthly share buyback progress: as of April 30, 2024, it had repurchased 11.1536 million shares (1.01% of total) for 177.86 million yuan at prices between 14.16 and 17.44 yuan per share.步长制药披露月度回购进展：截至2024年4月30日，已累计回购1115.36万股（占总股本1.01%），支付金额1.78亿元，回购价格区间14.16-17.44元/股。
2024-06-03Buchang Pharma repurchased 21.7875 million shares (1.97% of total equity) via centralized bidding as of May 31, 2024, spending CNY 351 million at prices between CNY 14.16 and 17.44 per share.步长制药截至2024年5月31日通过集中竞价累计回购2178.75万股（占总股本1.97%），支付总金额3.51亿元，成交价区间14.16-17.44元/股。
2024-06-14Buchang Pharma increased its share buyback plan from CNY 180-360 million to CNY 360-720 million, with a maximum price of CNY 24 per share, for employee stock ownership plans, equity incentives, or convertible bonds.步长制药将股份回购金额从1.8-3.6亿元增加至3.6-7.2亿元，回购价格上限24元/股，用于员工持股计划、股权激励或可转债。
2024-06-17As of June 17, 2024, Buchang Pharma had repurchased 22.2325 million shares (2.01% of total equity) via centralized bidding, spending a total of CNY 358 million.截至2024年6月17日，步长制药累计回购2223.25万股（占总股本2.01%），支付总金额3.58亿元。
2024-07-01As of June 30, 2024, repurchased 26.6347 million shares (2.41% of total equity) via centralized竞价 trading, at a total cost of RMB 425 million, with price range of RMB 14.16-17.44 per share.截至2024年6月30日，通过集中竞价交易累计回购股份2663.47万股（占总股本2.41%），总金额4.25亿元，价格区间14.16-17.44元/股。
2024-08-01Buchang Pharma repurchased 29.729 million shares (2.69% of total equity) via centralized bidding as of July 31, 2024, spending CNY 472.16 million at prices between CNY 14.16 and 17.44 per share.步长制药截至2024年7月31日通过集中竞价交易累计回购2972.9万股（占总股本2.69%），支付总金额4.72亿元，购买价格区间14.16-17.44元/股。
2024-09-18Share buyback update: as of Sep 18, 2024, company had repurchased 33.5555 million shares (3.03% of total) for RMB 528 million (max price RMB 17.44, min RMB 14.16).股份回购进展：截至2024年9月18日，公司累计回购3355.55万股（占总股本3.03%），支付金额5.28亿元（最高价17.44元，最低价14.16元）。
2024-10-08Buchang Pharma repurchased 10.6002 million shares (0.96% of total) in September 2024 for 163 million yuan; cumulative repurchases reached 40.3293 million shares (3.65%) for 635 million yuan.步长制药2024年9月回购1060.02万股（占总股本0.96%），金额1.63亿元；累计回购4032.93万股（3.65%），金额6.35亿元。
2024-10-31As of Oct 31, 2024, Buchang Pharma had cumulatively repurchased 41.397 million shares (3.74% of total) for 653 million yuan; October repurchases were 1.0677 million shares for 18.28 million yuan.截至2024年10月31日，步长制药累计回购4139.7万股（占总股本3.74%），金额6.53亿元；10月回购106.77万股，金额1828.37万元。
2024-11-05Cumulatively repurchased 44.277 million shares (4.00% of total equity) for 702 million yuan via centralized bidding; buyback price range 14.16-17.44 yuan/share.累计回购股份4427.73万股（占总股本4.00%），支付金额7.02亿元，回购价格区间14.16-17.44元/股。
2024-12-26Announced share buyback plan of 50-100 million yuan at up to 23 yuan/share, funded by自有资金 and financial institution special loan, for equity incentives, ESOP, or convertible bonds.公告拟以0.5-1亿元回购股份，价格不超过23元/股，资金来自自有资金及金融机构专项借款，用于股权激励、员工持股计划或可转债。
2025-01-05Announced share buyback plan of CNY 50-100 million at up to CNY 23/share, for employee stock ownership, equity incentives, or convertible bond conversion.公告拟以0.5-1.0亿元回购股份，回购价格不超过23元/股，用于员工持股计划、股权激励或可转债转股。
2025-01-21First tranche of share buyback executed: 1,268,600 shares (0.11% of total) repurchased at CNY 14.55-14.89/share, total amount CNY 18.73 million.首次回购股份126.86万股（占总股本0.11%），回购价格14.55-14.89元/股，总金额1873万元。
2025-02-06As of Jan 31, 2025, the company repurchased 1,268,600 shares (0.11% of total) via centralized竞价 trading, at prices between RMB 14.55 and 14.89 per share, totaling RMB 18.73 million (excluding fees).截至2025年1月31日，公司通过集中竞价交易累计回购股份126.86万股（占总股本0.11%），购买价格区间14.55-14.89元/股，总金额1873.07万元（不含交易费用）。
2025-04-01Buchang Pharma announced that as of March 31, 2025, it had repurchased 3,210,530 shares (0.29% of total equity) for a total of RMB 47.75 million, with prices ranging from RMB 14.55 to 15.06 per share.步长制药公告，截至2025年3月31日，已累计回购股份3,210,530股（占总股本0.29%），总金额4775万元，价格区间14.55-15.06元/股。
2025-05-09Completed share buyback: repurchased 6,620,630 shares (0.60% of total) for RMB 98.06 million at prices between RMB 13.86 and 15.07 per share.完成股份回购：累计回购6,620,630股（占总股本0.60%），耗资约9,806万元，回购价格区间13.86元/股至15.07元/股。
2026-01-16Board approved a share buyback plan of 60-120 million yuan at up to 23.98 yuan/share, funded by自有资金 and a 100 million yuan special loan from Agricultural Bank of China (2% p.a., 3-year), for equity incentives, ESOP, or convertible bonds.董事会审议通过0.6亿元至1.2亿元股份回购方案，回购价不超23.98元/股，资金来自自有资金及农业银行1亿元专项贷款（年利率2%，期限3年），用于股权激励、员工持股计划或可转债。
2026-02-26Completed a CNY 119 million share buyback within less than one month in early-to-mid February 2026.在2月中上旬不足一个月内完成1.19亿元股份回购。
2026-05-25Board approves share buyback of 75-150 million yuan at ≤21 yuan/share, funded by own funds (≥10%) and a 100 million yuan special loan from Minsheng Bank Heze Branch (1.8% p.a., 3-year term), for employee stock plans, equity incentives, or convertible bonds.董事会批准以0.75亿-1.5亿元回购股份，价格不超21元/股，资金来自自有资金（≥10%）及民生银行菏泽分行1亿元专项贷款（年利率1.8%，期限3年），用于员工持股、股权激励或可转债。
2026-06-02First share buyback executed: 1,974,600 shares (0.19% of total) repurchased at 14.98-15.33 yuan/share, total cost 29.98 million yuan.首次实施股份回购：回购1,974,600股（占总股本0.19%），价格区间14.98-15.33元/股，总金额2998.13万元。
2026-06-22Share buyback completed: total 9,821,996 shares (0.93% of total) repurchased at 14.42-15.64 yuan/share, total cost 150 million yuan, reaching the upper limit of the plan.股份回购完成：累计回购9,821,996股（占总股本0.93%），价格区间14.42-15.64元/股，总金额1.5亿元，达回购上限。
BC001 (anti-VEGFR2 mAb) clinical & licensingBC001（抗VEGFR2单抗）临床与授权
4 · 2024-02-27 → 2026-01-23
▾
BC001 injection received clinical trial approval; licensed to Russia's LANCET for Eurasian region.BC001注射液获临床试验批准；授权俄罗斯LANCET公司拓展欧亚市场。
2024-02-27Subsidiary Sichuan Luzhou Buchang Bio received NMPA clinical trial approval for injection BC001 (anti-VEGFR2 fully human mAb) combined with PD-1 inhibitor for advanced/metastatic solid tumors, including HER2-negative gastric/gastroesophageal junction adenocarcinoma; R&D cost 182.03 million yuan as of Jan 31, 2024.控股子公司四川泸州步长生物制药获国家药监局批准，注射用BC001（抗VEGFR2全人单抗）联合PD-1单抗治疗晚期/转移性实体瘤（含HER2阴性胃/胃食管交界处腺癌）临床试验；截至2024年1月31日研发投入约1.82亿元。
2024-08-14Buchang Pharma's controlled subsidiary Luzhou Buchang signed a Distribution and License Agreement with Russian company LANCET to license BC001 (injection for cancer treatment, including advanced gastric and gastroesophageal junction adenocarcinoma) for registration, packaging, quality control, and exclusive distribution in the Eurasian Economic Union and Uzbekistan.步长制药控股子公司泸州步长与俄罗斯公司LANCET签署经销和许可协议，许可其在欧亚经济联盟和乌兹别克斯坦内对注射用BC001（用于癌症治疗，包括晚期胃癌及胃食管交接处腺癌）进行注册、包装、质量控制及独家商业化。
2024-09-02Buchang Pharma signed a licensing agreement with Russian company LANCET.步长制药与俄罗斯公司LANCET签订许可协议。
2026-01-23Controlling subsidiary Luzhou Buchang signed an agreement with Russia's LANCET company in 2024 to authorize registration and commercialization of injection BC001 in the Eurasian Economic Union.控股子公司泸州步长2024年与俄罗斯LANCET公司签署协议，授权注射用BC001在欧亚经济联盟的注册与商业化推广。
Guarantee provisions for subsidiaries为子公司提供担保
15 · 2024-02-27 → 2026-05-29
▾
Provided numerous guarantees to banks for subsidiary loans, totaling billions of yuan.多次为子公司银行贷款向银行提供担保，总额达数十亿元。
2024-02-27Buchang Pharma and its subsidiaries provided total guarantees of approximately 2.657 billion yuan, accounting for 21.49% of audited net assets at end-2022.步长制药及控股子公司已提供担保总额约26.57亿元，占2022年末经审计净资产的21.49%。
2025-01-17Fulfilled guarantee obligation of CNY 5.01 million for controlled subsidiary Changrui Bio after it failed to repay loan; remaining guarantee balance CNY 5 million.因控股子公司长睿生物经营困难无还款能力，公司履行担保责任偿付贷款本息501.46万元，担保余额500万元。
2025-02-20The company provided an external guarantee of RMB 450 million (joint liability) to subsidiary Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.公司为子公司四川泸州步长生物制药有限公司提供4.5亿元连带责任担保。
2025-04-11Buchang Pharma provided a RMB 20 million guarantee to its subsidiary Shaanxi Buchang for a working capital loan from Huaxia Bank Xi'an Branch, with joint liability.步长制药为子公司陕西步长向华夏银行西安分行的流动资金借款提供2000万元连带责任担保。
2025-06-25Company provided a 10 million yuan joint liability guarantee to Luzhou Buchang for working capital loan from Sichuan Luxian Rural Commercial Bank.公司为泸州步长向四川泸县农村商业银行的流动资金借款提供1000万元连带责任保证担保。
2025-08-21Company provided a RMB 30 million joint liability guarantee to CITIC Bank Xi'an Branch for wholly-owned subsidiary Yangling Buchang Pharmaceutical, valid from August 20, 2025 to June 17, 2027.公司为全资子公司杨凌步长制药向中信银行西安分行提供3000万元连带责任保证，有效期自2025年8月20日至2027年6月17日。
2025-09-02Buchang Pharma disclosed a 100 million yuan guarantee for subsidiary Yangling Buchang Pharmaceutical, with total guarantees reaching 2.54 billion yuan (24.86% of 2024 audited net assets).步长制药披露为子公司杨凌步长提供1亿元担保，总担保额达25.4亿元（占2024年末净资产的24.86%）。
2025-10-17Provided a RMB 20 million joint liability guarantee to Chengdu Rural Commercial Bank Luzhou Branch for subsidiary Luzhou Buchang's working capital loan.为控股子公司泸州步长向成都农商银行泸州分行的2000万元流动资金借款提供连带责任保证担保。
2025-11-21Buchang Pharma signed two maximum guarantee contracts with Shanghai Rural Commercial Bank Jinshan Branch, providing 130 million yuan guarantee for Shanghai Hepu Medical Technology and 26 million yuan for Shanghai Hepu Medical Devices.步长制药与上海农商银行金山支行签订两份最高额保证合同，为上海合璞医疗科技提供1.3亿元、为上海合璞医疗器械提供2600万元连带责任保证。
2026-01-21Company signed a 50 million yuan maximum guarantee contract with Guangfa Bank Shanghai Branch for controlling subsidiary Shanghai He Pu Medical Technology's credit facility.公司与广发银行上海分行签订5000万元最高额保证合同，为控股子公司上海合璞医疗科技的授信额度提供担保。
2026-01-27Company signed a 30 million yuan maximum guarantee contract with Bank of Beijing Beijing Economic-Technological Development Area Sub-branch for controlling subsidiary Beijing Boyuan Runbu Pharmaceutical R&D.公司与北京银行北京经济技术开发区分行签订3000万元最高额保证合同，为控股子公司北京博源润步医药研发提供担保。
2026-03-25Company provides total guarantees of 730 million yuan for subsidiaries: 700 million yuan for Sichuan Luzhou Buchang Bio-Pharmaceutical's fixed-asset loan, and 30 million yuan for Beijing Boyuan Runbu Pharmaceutical R&D's credit line.公司为子公司提供合计7.3亿元担保：为四川泸州步长生物制药的固定资产借款担保7亿元，为北京博源润步医药研发的授信合同担保3000万元。
2026-04-15Provided a 30 million yuan joint liability guarantee to Beijing Bank Shanghai Branch for subsidiary Shanghai Hepu Medical Devices' comprehensive credit facility.为控股子公司上海合璞医疗器械有限公司与北京银行上海分行签订的《综合授信合同》提供3000万元连带责任保证。
2026-05-27Buchang provides a 300 million yuan guarantee (joint liability) to Beijing Bank Xi'an Branch for subsidiary Shaanxi Buchang Pharmaceutical's daily operations.步长制药为子公司陕西步长制药向北京银行西安分行提供3亿元连带责任担保，用于日常经营。
2026-05-29Buchang signs a 10 million yuan joint liability guarantee contract with Industrial Bank Luzhou Branch for subsidiary Sichuan Luzhou Buchang Bio's working capital loan.步长制药与兴业银行泸州分行签订1000万元连带责任保证合同，为子公司四川泸州步长生物的流动资金借款提供担保。
Regulatory warnings on shareholder Suzhou Liansheng Chemical stake股东苏州联胜化学持股监管警示
3 · 2024-03-06 → 2024-07-03
▾
Shareholders received regulatory warnings and CSRC warning letters for failing to timely disclose 5% stake.股东因未及时披露持股达5%收到上交所监管警示和山东证监局警示函。
2024-03-06Shareholder Suzhou Liansheng Chemical, Liu Shaoluan, and Yang Wei increased stake to 5% via exchange trading from Jan 4, 2019 to Feb 5, 2024.股东苏州联胜化学有限公司、刘少鸾、杨伟通过交易所竞价交易系统增持股份至5%（2019年1月4日至2024年2月5日）。
2024-06-13Shanghai Stock Exchange issued a regulatory warning to Buchang Pharma's shareholders Suzhou Liansheng Chemical, Liu Shaoluan, and Yang Wei for failing to timely disclose equity changes when their combined stake reached 5% (55,395,127 shares) on Feb 5, 2024.上交所对步长制药股东苏州联胜化学、刘少鸾、杨伟予以监管警示，因其合计持股达5%（55,395,127股）时未及时履行权益变动披露义务。
2024-07-03Shareholders Suzhou Liansheng Chemical, Liu Shaoluan, and Yang Wei received a warning letter from Shandong CSRC for failing to timely disclose reaching 5% shareholding (55,315,127 shares) until March 7, 2024.股东苏州联胜化学有限公司、刘少鸾、杨伟因合计持股达5%未及时披露（迟至2024年3月7日），收到山东证监局警示函。
Luzhou Buchang Biopharmaceutical equity & restructuring泸州步长生物制药股权与重组
4 · 2024-03-07 → 2025-06-16
▾
Terminated equity transfer agreement with Chen Junping and Wang Baocai; completed equity restructuring to 97.95% control.终止与陈俊平、王宝才的股权转让协议；完成股权重组至97.95%控股。
2024-03-07Buchang Pharma terminated the equity transfer agreement for Sichuan Luzhou Buchang Biopharmaceutical with Chen Junping and Wang Baocai, signing a supplementary agreement to return shares.步长制药与陈隽平、王宝才解除《四川泸州步长生物制药有限公司股权转让协议》，签署补充协议返还股权。
2025-03-07Buchang Pharma waives pre-emptive right for 2% equity in Luzhou Buchang, which shareholder Sichuan Tianrunyuan transfers to Hainan Qihongsheng for RMB 8.8M; company's stake remains 96.8636%.步长制药放弃对泸州步长2%股权的优先受让权，该股权由四川天润元以880万元转让给海南祺泓盛；公司持股比例维持96.8636%。
2025-05-22Controlling subsidiary Luzhou Buchang completed industrial and commercial registration for a 2% equity transfer to employee stock ownership platform Hainan Qihongsheng, with Buchang maintaining 96.8636% control.控股子公司泸州步长完成2%股权向员工持股平台海南祺泓盛的工商变更登记，步长制药持股比例保持96.8636%。
2025-06-16Controlling subsidiary Luzhou Buchang completed industrial and commercial registration after terminating a 2021 equity transfer agreement with Chen Junping and Wang Baocai; Buchang Pharma now holds 97.9545% stake.控股子公司泸州步长完成工商变更登记，终止与陈隽平、王宝才2021年签订的股权转让协议；步长制药持股比例变为97.9545%。
New subsidiary establishment spree (2024-2026)新设子公司热潮（2024-2026）
35 · 2024-03-08 → 2026-04-07
▾
Established numerous trading, medical device, cosmetics, and technology subsidiaries across China.在全国范围内设立多家贸易、医疗器械、化妆品及科技子公司。
2024-03-08Buchang Pharma plans to invest 9.4 million yuan to set up a 94%-owned subsidiary Shandong Buchang Trade Co., Ltd.步长制药拟出资940万元设立控股子公司“山东步长贸易有限公司”，持股比例94%。
2024-04-09Controlling subsidiary Luzhou Buchang Biopharmaceutical plans to invest 25 million yuan to set up a wholly-owned subsidiary Beijing Boyuan Runbu Pharmaceutical R&D Co., Ltd.控股子公司四川泸州步长生物制药拟出资2500万元设立全资子公司北京博源润步医药研发有限公司。
2024-04-23Beijing Boyuan Runbu Pharmaceutical R&D Co., Ltd. was established with registered capital of 25 million yuan, wholly owned by Luzhou Buchang Biopharmaceutical, legal representative Yang Chun.北京博源润步医药研发有限公司成立，注册资本2500万元，由四川泸州步长生物制药全资持股，法定代表人杨春。
2024-05-17Buchang Pharma co-founded Shandong Buchang Cosmeceutical Biotechnology Co., Ltd. with a registered capital of 10 million yuan, engaging in cosmetics, daily chemical products, and Class I medical device sales.步长制药与赵路等共同成立山东步长药妆生物科技有限公司，注册资本1000万元，经营范围包括化妆品、日用化学产品、第一类医疗器械销售等。
2024-05-22Buchang Pharma's controlled subsidiary Jinan Buchang Shengyuan formed a joint venture Hangzhou Buchang Network Technology Co., Ltd. with Hangzhou Paizhou Brand Management, with registered capital of 3 million yuan; Buchang holds 51% (1.53 million yuan) and Paizhou holds 49%.步长制药控股子公司济南步长晟源与杭州湃舟品牌管理共同投资设立合资公司杭州步长网络科技有限公司，注册资本300万元，步长持股51%（出资153万元），湃舟持股49%。
2024-07-30Planned to invest RMB 1.9 million to establish a 95%-owned subsidiary, Shandong Buchang Dingshun Pharmaceutical Co., Ltd., to enhance strategic layout and market competitiveness.拟出资190万元设立控股子公司山东步长鼎顺药业有限公司（持股95%），以完善战略发展布局并获取市场竞争优势。
2024-09-12Board approved changing registered capital of proposed subsidiary 'Shandong Buchang Dingshun Pharmaceutical Co., Ltd.' from RMB 2 million to RMB 3 million.董事会审议通过将拟设控股子公司“山东步长鼎顺药业有限公司”注册资本由200万元变更为300万元。
2024-10-18Buchang Pharma's board approved expanding the business scope of a proposed new subsidiary to include 'drug retail' and 'health food (pre-packaged) sales'.步长制药董事会批准拟新设子公司经营范围增加'药品零售''保健食品（预包装）销售'。
2024-11-22Planned to invest 11.13 million yuan to set up six wholly-controlled subsidiaries: Shandong Buchang Chuanfang Pharma, Buchang Lianchuang Commerce, Buchang Dingxin Commerce, Buchang Mailitong Commerce, Buchang Zhongfushou Pharma, Shandong Buchang Ruifeng Technology.拟出资1113万元设立六家控股子公司：山东步长传方药业、步长联创商贸、步长鼎鑫商贸、步长脉利通商贸、步长众福寿药业、山东步长瑞丰科技。
2024-12-06Planned to invest 31.5 million yuan to set up five wholly-controlled subsidiaries: Shandong Buchang Golden Key Medical Technology, Jinan Buchang Jianxin Biotechnology, Shandong Buchang Changyan Biotechnology, Shandong Buchang Guanyou Medical Devices, Shandong Buchang Zhongxinkang Medical Technology.拟出资3150万元设立五家控股子公司：山东步长金钥匙医药科技有限公司、济南步长建鑫生物科技有限公司、山东步长畅妍生物科技有限公司、山东步长冠优医疗器械有限公司、山东步长众鑫康医药科技有限公司。
2024-12-06Changed shareholder of proposed subsidiary Shandong Buchang Ruifeng Technology from Wu Jinhuan to Xia Zengwu; Buchang invests 4.6 million yuan for 92% stake.拟设子公司山东步长瑞丰科技有限公司股东由武金焕变更为夏增虎，步长出资460万元持股92%。
2024-12-30Signed formal cooperation agreements for the establishment of six controlled subsidiaries, including Shandong Buchang Chuanfang Pharmaceutical (Buchang 94%, 2.82 million yuan) and Shandong Buchang Youpin Medical Technology (Buchang 92%, 4.6 million yuan).正式签署协议设立六家控股子公司，包括山东步长传方药业（步长94%，282万元）和山东步长优品医疗科技（步长92%，460万元）。
2025-01-07Invested CNY 11.13 million to set up six controlled subsidiaries, including Shandong Buchang Chuanfang Pharmaceutical, with over 90% stake in each.出资1113万元设立六家控股子公司（包括山东步长传方药业等），持股比例均超过90%。
2025-01-08Planned to invest in new controlled subsidiary Shandong Buchang Zhenze Pharmaceutical Technology (registered capital not disclosed) for strategic layout, with employee co-investment.拟投资设立控股子公司山东步长臻泽医药科技有限公司，完善战略布局，相关人员跟投。
2025-01-10New subsidiary Shandong Buchang Changyan Biotechnology established with registered capital of CNY 10 million, co-held by Buchang Pharmaceutical, covering Class I/II medical devices and cosmetics wholesale.新设子公司山东步长畅妍生物科技有限公司成立，注册资本1000万元，步长制药等共同持股，经营范围包括一类/二类医疗器械销售、化妆品批发。
2025-01-13Three new subsidiaries established: Shandong Buchang Youpin Medical Technology, Shandong Buchang Zhongxinkang Pharmaceutical, Shandong Buchang Jinyaoshi Pharmaceutical, each with CNY 5 million registered capital, all majority-owned by Buchang Pharmaceutical, covering cosmetics and medical device sales.三家新子公司成立：山东步长优品医疗科技、山东步长众鑫康医药科技、山东步长金钥匙医药科技，注册资本各500万元，步长制药为大股东，经营范围包括化妆品和医疗器械销售。
2025-01-21New subsidiary Jinan Buchang Jianxin Biotechnology established with registered capital of CNY 10 million, co-held by Buchang Pharmaceutical, covering Class I/II medical devices, cosmetics wholesale, and warehousing.新设子公司济南步长建鑫生物科技有限公司成立，注册资本1000万元，步长制药等共同持股，经营范围包括一类/二类医疗器械销售、化妆品批发、仓储服务。
2025-02-17Three newly established wholly-owned trading subsidiaries – Jinan Buchang Chicheng, Jinan Buchang Caigan, and Jinan Buchang Yingxi – completed registration, each with registered capital of RMB 1 million, engaging in daily necessities and medical supplies wholesale.新设三家全资贸易子公司——济南步长驰骋商贸、济南步长财淦商贸、济南步长瀛玺商贸完成注册，注册资本各100万元，经营日用品及医疗用品批发。
2025-03-07Three new subsidiaries complete registration: Jinan Buchang Zhongfu Commerce, Shandong Buchang Guanyou Medical Devices (RMB 5M registered capital), and Shandong Buchang Zhenze Pharmaceutical Technology.三家新子公司完成工商登记：济南步长众福商贸有限公司、山东步长冠优医疗器械有限公司（注册资本500万元）、山东步长臻泽医药科技有限公司。
2025-04-01Buchang Pharma established three controlled subsidiaries: Buchang Zhongfushou Pharmaceutical (RMB 930,000), Shandong Buchang Guanyou Medical Devices (RMB 4.5 million), and Shandong Buchang Zhenze Pharmaceutical Technology (RMB 4.5 million).步长制药设立三家控股子公司：步长众福寿药业（93万元）、山东步长冠优医疗器械（450万元）、山东步长臻泽医药科技（450万元）。
2025-04-02Buchang Pharma signed supplementary agreements with partners to extend the capital contribution deadline for six newly established subsidiaries (e.g., Shandong Buchang Jinyaoshi, Jinan Buchang Jianxin) from 3-6 months to five years.步长制药与合作伙伴签署补充协议，将六家新设子公司（如山东步长金钥匙、济南步长建鑫等）的注册资本实缴期限从3-6个月延长至五年。
2025-06-10Board approved change of domicile for subsidiary Buchang Changyan and change of domicile and name for subsidiary Jinan Buchang Jianxin to Hangzhou Buchang Jianxin Biotechnology Co., Ltd.董事会审议通过控股子公司步长畅妍住所变更，以及济南步长建鑫更名为杭州步长建鑫生物科技有限公司并迁址杭州。
2025-06-20Controlling subsidiary Shandong Buchang Chuanfang plans to invest 4 million yuan (80% stake) to jointly set up Shaanxi Buchang Yishu Pharmaceutical Co., Ltd. with Lingyi Digital (Shaanxi) Internet Technology (20% stake), registered capital 5 million yuan.控股子公司山东步长传方拟出资400万元（持股80%）与零医数术（陕西）互联网科技共同设立陕西步长医数药业有限公司，注册资本500万元。
2025-07-18Subsidiary Shandong Buchang Chuanfang signed JV agreement with Lingyi Digital (Shaanxi) to establish Shaanxi Buchang Yishu Pharmaceutical (tentative name) with registered capital 5 million yuan; Buchang Chuanfang holds 80%, Lingyi holds 20%.控股子公司山东步长传方与零医数术（陕西）签署协议，共同投资设立陕西步长医数药业（暂定名），注册资本500万元，步长传方持股80%，零医数术持股20%。
2025-08-08Controlled subsidiary Jinan Buchang Caigan plans to relocate registered address from Jinan, Shandong to Hengqin New Area, Zhuhai, Guangdong, and rename to 'Buchang Qingsong Dahealth (Hengqin) Co., Ltd.' or similar, to optimize strategic layout in the Greater Bay Area.控股子公司济南步长财淦计划将注册地址从山东济南迁至广东珠海横琴新区，并更名为‘步长青松大健康（横琴）有限公司’或类似名称，以优化大湾区战略布局。
2025-08-15Controlled subsidiary Buchang Jianxin completed industrial and commercial registration changes, relocating from Jinan to Hangzhou Xiaoshan District and renaming to 'Hangzhou Buchang Jianxin Biotechnology Co., Ltd.'.控股子公司步长建鑫完成工商变更登记，从济南迁至杭州萧山区，并更名为‘杭州步长建鑫生物科技有限公司’。
2025-08-16Controlled subsidiary Buchang Jinyaoshi's registered address changed within Jinan Laiwu High-tech Zone, approved by the board for operational needs.控股子公司步长金钥匙注册地址在济南莱芜高新区内变更，经董事会批准以满足经营管理需要。
2025-09-08Buchang Pharma's subsidiary Shandong Buchang Chuanfang invested 4 million yuan (80%) to jointly establish Shaanxi Buchang Shushu Pharmaceutical with Lingyi Digital (Shaanxi) (1 million yuan, 20%), with registered capital of 5 million yuan; the new company completed registration.步长制药控股子公司山东步长传方出资400万元（80%）与零医数术（陕西）（出资100万元，20%）共同投资设立陕西步长数术药业有限责任公司，注册资本500万元，已完成工商登记。
2025-11-01Buchang Pharma's controlled subsidiary Shandong Buchang Youpin Medical Technology completed its registered address change to Laiwu High-tech Zone, with new business scope including health food and disposable medical supplies sales.步长制药控股子公司山东步长优品医疗科技完成住所变更至莱芜高新区，经营范围新增保健食品和一次性医疗用品销售。
2025-11-20Buchang Pharma's controlled subsidiary Jinan Buchang Caigan Trading completed its registered address change to Laiwu High-tech Zone.步长制药控股子公司济南步长财淦商贸完成住所变更至莱芜高新区。
2025-12-10Controlled subsidiary Buchang Golden Key invested RMB 510,000 (51%) to jointly establish Zhuhai Daqianmo Buchang Pharmaceutical Technology Co., Ltd. with Yin Weiqun (49%), registered capital RMB 1M, located in Hengqin, Zhuhai, covering cosmetics wholesale, medical device sales, etc.控股子公司步长金钥匙出资51万元（持股51%）与尹卫群（持股49%）共同设立珠海大阡陌步长医药科技有限公司，注册资本100万元，位于珠海横琴，经营范围包括化妆品批发、医疗器械销售等。
2025-12-12Controlled subsidiary Zhejiang Huapai Bio jointly invested to establish Nanjing Keyinuo Biotechnology Co., Ltd. (registered capital RMB 2M) with Hefei Keyinuo Biotechnology, Jiangsu Industrial Technology Research Institute, and Hefei Kesaise Enterprise Partnership, completed industrial registration on 2025-12-12, covering drug production and biotech R&D.控股子公司浙江华派生物与合肥科医诺生物、江苏省产业技术研究院等共同投资设立南京科医诺生物科技有限公司（注册资本200万元），于2025年12月12日完成工商登记，经营范围涵盖药品生产和生物医药研发。
2025-12-24Controlled subsidiary Buchang Zhongxinkang Pharmaceutical invested RMB 1.8M (60%) to jointly establish Buchang Internet (Hubei) Co., Ltd. with Hubei Hejun Tengteng Trade (40%), registered capital RMB 3M, located in Caidian, Wuhan, covering medical device internet information services and food internet sales.控股子公司步长众鑫康医药出资180万元（持股60%）与湖北合俊腾辉贸易（持股40%）共同设立步长互联网（湖北）有限公司，注册资本300万元，位于武汉蔡甸，经营范围包括医疗器械互联网信息服务和食品互联网销售。
2026-01-14New subsidiary Shandong Buchang Guanyou Medical Devices Co., Ltd. was established in 2025 to focus on localized operation and supply chain control in the medical device sector.2025年新设山东步长冠优医疗器械有限公司，聚焦医疗器械领域本土化运营与供应链管控。
2026-04-07Board approved a 3 million yuan capital increase to subsidiary Jinan Buchang Caijin (renamed to Buchang Jialin Health Technology (Jinan) Co., Ltd.), with Buchang contributing 2.7 million yuan, raising registered capital from 1 million to 4 million yuan.董事会批准向子公司济南步长财淦商贸有限公司增资300万元（步长出资270万元），注册资本由100万元增至400万元，并更名为步长嘉林大健康科技(济南)有限公司。
Other developments其他动态
19 · 2024-03-08 → 2026-06-22
▾
Assorted developments not part of a running storyline.未归入某条故事线的零散动态。
2024-03-08Buchang Pharma and its subsidiaries authorized securities investment of up to 30 million yuan of self-owned funds.步长制药及相关子公司拟对最高额度不超过3000万元的自有资金进行证券投资。
2024-05-31Buchang Pharma's controlled subsidiary Qionglai Tianyin implemented an equity incentive plan for senior management and key employees via capital increase, raising registered capital from 200 million to 203 million yuan; Buchang's stake diluted from 92.75% to 91.3793%.步长制药控股子公司邛崃天银通过增资扩股对高管及骨干员工实施股权激励，注册资本由2亿元增至2.03亿元；步长持股比例由92.75%降至91.3793%。
2024-10-09At the 2024 semi-annual performance briefing, Buchang Pharma stated it has not received any major shareholder reduction notice.在2024年半年度业绩说明会上，步长制药表示未收到大股东减持计划通知。
2024-11-20Wholly-owned subsidiary Shaanxi Buchang's Ren Zhi Jiang Tang Capsule approved as first Category 2 TCM protected variety by NMPA; for adjunctive treatment of type 2 diabetes; protection period 7 years.全资子公司陕西步长的人知降糖胶囊获国家药监局批准为首家中药二级保护品种，用于Ⅱ型糖尿病辅助治疗，保护期七年。
2024-12-26Agreed to terminate the Development, Supply and Sales Agreement with Nantong Lianya for 5 products including Nifedipine Extended-Release Tablets; Nantong Lianya to refund 20.58 million yuan of R&D fees.与南通联亚终止硝苯地平缓释片等5个产品的《开发、供应及销售协议》，南通联亚退回研发费用2058万元。
2025-03-04Deputy Chair Zhao Jing proposes at the Two Sessions to use AI to empower TCM inheritance and innovation, including data standards and smart manufacturing.副董事长赵菁在两会上提议利用AI赋能中医药传承创新，包括数据标准和智能制造。
2025-03-07Buchang Pharma plans to use up to RMB 30M of自有资金 for securities investment, with rolling usage allowed within the cap.步长制药拟使用不超过3000万元自有资金进行证券投资，额度内资金可滚动使用。
2025-04-30Buchang Pharma stated on the investor interactive platform that it currently has no plan to develop a pill formulation of its main product Wenxin Granules (稳心颗粒).步长制药在互动平台表示，目前暂无主要产品稳心颗粒的丸剂研究开发计划。
2025-05-23Subsidiary Shaanxi Modern Innovation Traditional Chinese Medicine Research Institute's 'Innovative TCM Green Intelligent Pilot Platform' was selected for the first batch of key cultivated pilot platforms by MIIT.子公司陕西现代创新中药研究院有限公司的“创新中药绿色智能中试平台”入选工信部首批重点培育中试平台名单。
2025-10-08Investee company Qilekang Digital Health's VIE-controlled entity POMDOCTOR LIMITED (Shiliuyunyi) listed on Nasdaq (ticker: POM). Buchang holds 2,957,613 shares (~15%) via subsidiary Danhong (HK) Technology.参股公司七乐康数字医疗的VIE控股实体石榴云医有限公司在纳斯达克上市（代码：POM）。步长通过子公司丹红（香港）科技持有2,957,613股（约15%）。
2025-12-17Wholly-owned subsidiary Shandong Danhong received a Drug Registration Application Termination Notice from NMPA for Empagliflozin Tablets (type 2 diabetes), voluntarily withdrawing the application to improve submission data. R&D expenses incurred were approximately RMB 15.01M. Company plans to resubmit after completing studies.全资子公司山东丹红收到国家药监局关于恩格列净片（2型糖尿病）的《药品注册申请终止通知书》，因需完善申报资料主动撤回上市申请，已投入研发费用约1501万元，公司计划完善研究后重新提交。
2026-01-12Investment in Qilekang Digital Medical (POMDOCTOR LIMITED / Shiliuyunyi) is expected to record a fair value loss of 293 million yuan in 2025 due to the US-listed entity's stock price collapse.参股公司七乐康数字医疗（石榴云医）因美股上市主体股价暴跌，预计2025年确认公允价值变动损失2.93亿元。
2026-02-26Six products from four subsidiaries were provisionally selected in the national centralized drug procurement follow-up bidding for expired agreement varieties.旗下四家子公司6个品种在国家组织集采药品协议期满品种接续采购中拟中选。
2026-02-27Subsidiary's drug Clindamycin Hydrochloride Capsules passed consistency evaluation for generic drug quality and efficacy after process/formulation change.控股子公司药品盐酸克林霉素胶囊通过工艺处方变更的仿制药质量和疗效一致性评价。
2026-04-01Subsidiary's Clindamycin Hydrochloride Capsule passed consistency evaluation for generic drug quality and efficacy after process/formulation change.控股子公司药品盐酸克林霉素胶囊通过工艺处方变更的仿制药质量和疗效一致性评价。
2026-05-15Wholly-owned subsidiary Baoding Tianhao transfers the in-process project 'Recombinant Human Brain Natriuretic Peptide for Injection' to controlling subsidiary Sichuan Luzhou Buchang Bio for 121.2941 million yuan.全资子公司保定天浩将'注射用重组人脑利钠肽'在研项目转让给控股子公司四川泸州步长生物，交易金额12,129.41万元。
2026-06-05NDA for Bai Dai Wan (White Discharge Pill) accepted by NMPA's Center for Drug Evaluation, acceptance number CYZB2602512.白带丸药品注册申请获国家药监局药品审评中心受理，受理号CYZB2602512。
2026-06-15Controlling subsidiary's drug Clindamycin Hydrochloride Capsule passes consistency evaluation for generic drugs after process/formulation change.控股子公司药品盐酸克林霉素胶囊通过工艺处方变更的仿制药质量和疗效一致性评价。
2026-06-22Controlling subsidiary Buchang Caijin renamed to Buchang Jialin Pharmaceutical Technology (Jinan) Co., Ltd., and completed capital increase of 3 million yuan by all shareholders pro rata.控股子公司步长财淦更名为步长嘉林医药科技(济南)有限公司，并完成全体股东按持股比例增资300万元。
Shandong Danhong Pharmaceutical production & GMP山东丹红制药生产与GMP
9 · 2024-03-28 → 2026-01-21
▾
Added small-volume injection workshop, extraction workshop; obtained GMP certificates and production license amendments.新增小容量注射剂车间、提取车间；获得GMP证书及生产许可变更。
2024-03-28Wholly-owned subsidiary Shandong Danhong Pharma obtained Shandong FDA approval to add a small-volume injection workshop and production approval numbers for entrusted products (Desloratadine tablets, Pregabalin capsules).全资子公司山东丹红制药有限公司获山东省药监局许可，新增小容量注射剂车间及委托生产产品（地氯雷他定片、普瑞巴林胶囊）批准文号。
2024-04-03Wholly-owned subsidiary Shandong Danhong Pharmaceutical obtained Drug GMP Compliance Inspection Notice from Shandong Medical Products Administration for small-volume injection production line (Preparation I workshop).全资子公司山东丹红制药获得山东省药监局签发的药品GMP符合性检查告知书，涉及小容量注射剂生产线（制剂I车间）。
2024-10-15Wholly-owned subsidiary Shandong Danhong Pharmaceutical obtained Shandong Medical Products Administration approval to add entrusted production on its Drug Manufacturing License, valid until Nov 2, 2025.全资子公司山东丹红制药获山东省药监局许可，在《药品生产许可证》副本增加委托生产，有效期至2025年11月2日。
2025-01-22Wholly-owned subsidiary Shandong Danhong obtained Shandong Drug Administration approval to add extraction workshop (Workshop 2) for TCM pretreatment and extraction on its Drug Manufacturing License.全资子公司山东丹红获山东省药监局许可，在《药品生产许可证》副本增加提取二车间，用于中药前处理和中药提取。
2025-02-06Wholly-owned subsidiary Shandong Danhong obtained GMP compliance certificate for extraction workshop 2 (TCM pretreatment extraction line) with annual capacity of 94.5 million units (10ml spec), producing Danhong Injection, a proprietary product with 2023 sales of RMB 2.297 billion.全资子公司山东丹红获得提取二车间（中药前处理提取生产线）GMP符合性检查证书，设计产能9450万支/年（10ml规格），主要生产独家品种丹红注射液，2023年销售额22.97亿元。
2025-04-09Buchang Pharma's wholly-owned subsidiary Shandong Danhong obtained approval from Shandong Medical Products Administration to revise its Drug Manufacturing License, removing entrusted production of dapoxetine tablets, levetiracetam extended-release tablets, and sitagliptin phosphate tablets from Shaanxi Buchang due to marketing authorization holder changes.步长制药全资子公司山东丹红获山东省药监局批准变更《药品生产许可证》，因持有人变更，核减委托陕西步长生产盐酸达泊西汀片、左乙拉西坦缓释片、磷酸西格列汀片的生产范围。
2025-06-03Wholly-owned subsidiaries Shandong Kang'ai and Shandong Danhong obtained drug production license changes: Kang'ai added oral solution line; Danhong commissioned Yangling Buchang and Shaanxi Buchang Gaoxin to produce Sorafenib Tosylate and Atomoxetine HCl capsules until Nov 2, 2025.全资子公司山东康爱增加口服溶液剂生产线；山东丹红委托杨凌步长及陕西步长高新生产甲苯磺酸索拉非尼片和盐酸托莫西汀胶囊，委托生产有效期至2025年11月2日。
2025-08-12Subsidiary Shandong Danhong Pharmaceutical was recognized as a Shandong provincial 'Specialized and New' (专精特新) SME for its innovation in traditional Chinese medicine, holding 12 drug varieties and 20 approval numbers.子公司山东丹红制药因在中药领域的创新，被认定为山东省‘专精特新’中小企业，持有12个药品品种和20个药品批准文号。
2026-01-21Wholly-owned subsidiary Shandong Danhong Pharmaceutical obtained approval from Shandong Medical Products Administration to add entrusted production of Loxoprofen Sodium Oral Solution and Mirogabalin Besylate Tablets, and to add approval number for Ibuprofen Sustained-Release Capsules.全资子公司山东丹红制药获山东省药监局批准，新增委托生产洛索洛芬钠口服溶液和苯磺酸美洛加巴林片，并增加布洛芬缓释胶囊批准文号。
Intellectual property & technology transfer知识产权与技术转让
6 · 2024-04-09 → 2026-03-12
▾
Trademark licensing, technology transfer contracts, and acquisition of new drug or health food technologies.商标许可、技术转让合同及新药或保健食品技术收购。
2024-04-09Buchang Pharma and its wholly-owned subsidiary Shandong Buchang Pharmaceutical Sales licensed trademark to Shandong Huatao Pharmaceutical for 200,000 yuan per year, valid from 2024-04-08 to 2027-04-08, within mainland China only.步长制药及全资子公司山东步长医药销售许可山东华涛药业使用相关商标，每年许可费20万元，期限2024年4月8日至2027年4月8日，地域限于中国大陆。
2025-04-30Buchang Pharma registered the trademark 'Buchang Shenghuoguan' (步长生活馆) under international class 05 (pharmaceuticals), trademark registration number 79740178.步长制药申请注册‘步长生活馆’商标获核准，国际分类为05-医药，商标注册号79740178。
2025-08-15Controlled subsidiary Shandong Danhong signed a technology transfer contract with the Affiliated Hospital of Shandong University of Traditional Chinese Medicine to acquire the 'Erzhi Tiaojing Optimization Formula' technology ownership for RMB 15 million, for development of a Class 1.1 new TCM drug targeting ovarian reserve dysfunction.控股子公司山东丹红与山东中医药大学附属医院签署技术转让合同，以1500万元受让‘二至调经优化方’技术所有权，用于开发治疗卵巢储备功能减退的1.1类中药新药。
2025-11-14Buchang Pharma received NMPA approval for the transfer of the exclusive traditional Chinese medicine 'Xiaolin Baidu San' (消淋败毒散) marketing authorization holder from Shandong Kongfu Pharma to itself, with R&D investment of approximately 28.15 million yuan.步长制药获国家药监局批准，将独家品种“消淋败毒散”的上市许可持有人从山东孔府制药变更为自身，研发投入约2815万元。
2025-12-24Wholly-owned subsidiary Shandong Danhong signed a Technology Transfer Contract with Shaanxi Functional Food Engineering Center to acquire the technology ownership of 6 health foods (including Yunting Brand Ejiao Dihuang Oral Liquid) for RMB 7.5M.全资子公司山东丹红与陕西功能食品工程中心签署《技术转让合同》，以750万元受让云亭牌阿胶地黄口服液等6个保健食品的技术所有权。
2026-03-12Wholly-owned subsidiary Shandong Danhong plans to sign technology transfer and R&D cooperation contract with Hangzhou Hongyu Medical Technology for Yiqi Huoxue Jieyu Granules (Class 1.1 TCM new drug) for post-stroke depression.全资子公司山东丹红拟与杭州鸿育医药科技就益气活血解郁颗粒（1.1类中药新药）签署技术转让与科研合作合同，用于卒中后抑郁症。
Tonghua Guhong (通化谷红) & Jilin Tiancheng (吉林天成) goodwill impairment通化谷红与吉林天成商誉减值
5 · 2024-04-25 → 2025-04-29
▾
Repeated goodwill impairments due to products removed from medical insurance catalogs and key monitoring lists.因产品退出医保目录和纳入重点监控目录，多次计提商誉减值。
2024-04-25Buchang Pharma disclosed that it plans to impair goodwill of approximately 597 million yuan for subsidiaries Tonghua Guhong Pharmaceutical and Jilin Tiancheng Pharmaceutical, due to products being removed from provincial medical insurance catalogs and added to key monitoring lists.步长制药披露拟对通化谷红制药及吉林天成制药计提商誉减值准备约5.97亿元，原因系相关产品被调出省级医保目录并纳入重点监控目录。
2025-01-202024 annual results forecast: net loss attributable to parent of CNY 428-808 million vs profit of CNY 319 million in 2023; impairment of goodwill of CNY 700-1,000 million on Tonghua Guhong and Jilin Tiancheng; revenue decline due to products removed from medical insurance catalogs.2024年度业绩预告：归母净利润亏损4.28亿至8.08亿元（上年同期盈利3.19亿元）；拟对通化谷红和吉林天成计提商誉减值准备7亿至10亿元；部分产品因调出医保目录导致收入减少。
2025-02-10The company expects a net loss of RMB 428 million to 808 million for FY2024, primarily due to goodwill impairment of approximately RMB 700 million to 1 billion from acquisitions of Tonghua Guhong and Jilin Tiancheng.公司预计2024年归母净利润亏损4.28亿元至8.08亿元，主要因收购通化谷红和吉林天成形成的商誉计提减值准备约7亿元至10亿元。
2025-03-01Buchang Pharma expects 2024 net loss of RMB 428M-808M, citing RMB 700M-1B goodwill impairment for subsidiaries Tonghua Guhong and Jilin Tiancheng.步长制药预计2024年净亏损4.28亿-8.08亿元，因对子公司通化谷红和吉林天成计提7亿-10亿元商誉减值。
2025-04-29Buchang Pharma's 2024 annual report disclosed a goodwill impairment of RMB 853 million on subsidiaries Tonghua Guhong and Jilin Tiancheng, due to products being removed from provincial medical insurance catalogs and inclusion in key monitoring lists.步长制药2024年年报披露，对子公司通化谷红和吉林天成计提商誉减值准备8.53亿元，因产品被调出省级医保目录并纳入重点监控目录。
BC008-1A (anti-PD-1/TIGIT bispecific antibody) clinical developmentBC008-1A（抗PD-1/TIGIT双抗）临床开发
4 · 2024-04-26 → 2024-07-26
▾
BC008-1A injection received clinical trial approvals for multiple solid tumors; Phase Ib contract signed.BC008-1A注射液获多项实体瘤临床试验批准；签订Ib期临床合同。
2024-04-26Controlling subsidiary Luzhou Buchang Biopharmaceutical's investigational drug BC008-1A injection received NMPA acceptance for new indication clinical trial application, targeting glioblastoma and advanced solid tumors (non-small cell lung cancer, esophageal cancer).控股子公司四川泸州步长生物制药在研品种BC008-1A注射液新增适应症临床试验申请获国家药监局受理，拟用于胶质母细胞瘤及非小细胞肺癌、食管癌等晚期实体瘤。
2024-05-11Buchang Pharma's controlled subsidiary Sichuan Luzhou Buchang Biopharma received NMPA acceptance of a clinical trial application for its investigational drug BC008-1A Injection, with new indications including glioblastoma and advanced solid tumors such as non-small cell lung cancer and esophageal cancer.步长制药控股子公司四川泸州步长生物制药在研品种BC008-1A注射液新增适应症的临床试验申请获国家药监局受理，拟开展适应症为胶质母细胞瘤及非小细胞肺癌、食管癌等晚期实体瘤。
2024-07-09Subsidiary Sichuan Luzhou Buchang Biopharmaceutical received NMPA clinical trial approval for BC008-1A injection (anti-PD-1/TIGIT bispecific antibody) for new indications: glioblastoma, non-small cell lung cancer, esophageal cancer, and other advanced solid tumors; R&D investment ~RMB 77.81 million.控股子公司四川泸州步长生物制药获国家药监局批准，BC008-1A注射液（抗PD-1/TIGIT双特异性抗体）新增适应症临床试验，用于胶质母细胞瘤、非小细胞肺癌、食管癌等晚期实体瘤；研发投入约7781.45万元。
2024-07-26Subsidiary Luzhou Buchang signed a technical service contract with Zhengzhou Shenlanhai Biomedical Technology for a Phase Ib clinical study of BC008-1A injection combined with chemotherapy in advanced solid tumors, at a cost of RMB 22.46 million (tax included).控股子公司泸州步长与郑州深蓝海生物医药科技签订技术服务合同，委托开展BC008-1A注射液联合化疗在晚期实体瘤的Ib期临床研究，费用2246万元（含税）。
Naoxintong Capsule (脑心通胶囊) price adjustment & overseas registration脑心通胶囊价格调整与海外注册
3 · 2024-05-06 → 2024-08-02
▾
Price cut for main product Naoxintong Capsules in China; obtained Hong Kong registration.主要产品脑心通胶囊国内降价；获得香港注册证书。
2024-05-06Buchang Pharma's wholly-owned subsidiary Shaanxi Buchang Pharma lowered the listed price of its main product Naoxintong Capsules (36/48/72 capsules per box to 19.90/26.26/38.81 yuan) following NHC guidance; product accounted for 22.2% of 2023 revenue and 21.87% of Q1 2024 revenue.步长制药全资子公司陕西步长制药根据国家医保局文件精神，下调主要产品脑心通胶囊挂网价格（36粒/盒调至19.90元、48粒/盒调至26.26元、72粒/盒调至38.81元）；该产品2023年占营收22.2%，2024年一季度占21.87%。
2024-07-25Product Naoxintong Capsules passed registration approval from the Hong Kong Chinese Medicine Council, obtaining a Hong Kong Proprietary Chinese Medicine Registration Certificate.产品脑心通胶囊通过香港中医药管理委员会中药组注册审批，取得香港《中成药注册证明书》。
2024-08-02Buchang Pharma's product Naoxintong Capsule (脑心通胶囊) obtained a Hong Kong Chinese Medicine Registration Certificate (No. HKC-07262), valid until March 27, 2029, enabling sales as a proprietary Chinese medicine in Hong Kong.步长制药产品脑心通胶囊获得香港中成药注册证明书（编号HKC-07262），有效期至2029年3月27日，具备在香港以中成药身份销售资格。
Share pledges by controlling shareholder Buchang (Hong Kong)控股股东步长（香港）股份质押
8 · 2024-05-23 → 2026-05-12
▾
Controlling shareholder repeatedly pledged shares to various banks for operational needs.控股股东多次向多家银行质押股份用于运营需求。
2024-05-23Buchang Pharma's controlling shareholder Buchang (Hong Kong) Holdings pledged 5 million shares (0.45% of total) to China Construction Bank Guiyang Chaoyang Sub-branch.步长制药控股股东步长（香港）控股有限公司向中国建设银行贵阳朝阳支行质押500万股（占总股本0.45%）。
2024-12-18Controlling shareholder Buchang (Hong Kong) Holdings pledged an additional 2.45 million shares as supplementary pledge; cumulative pledged shares 74.93 million, representing 15.26% of its holdings and 6.77% of total shares.控股股东步长（香港）控股有限公司补充质押245万股；累计质押7493万股，占其持股15.26%，占总股本6.77%。
2025-02-10Controlling shareholder Buchang (Hong Kong) pledged 9 million shares (1.83% of its holding, 0.81% of total) to CITIC Financial Leasing; cumulative pledged shares reached 83.93 million (17.10% of its holding, 7.59% of total).控股股东步长（香港）向中信金融租赁质押900万股（占其持股1.83%，总股本0.81%）；累计质押8393万股（占其持股17.10%，总股本7.59%）。
2025-06-23Controlling shareholder Buchang (Hong Kong) pledged 19 million shares (1.72% of total) to CITIC Financial Leasing for operations, from June 20, 2025 to Oct 15, 2028.控股股东步长（香港）质押1900万股（占总股本1.72%）给中信金融租赁，用于经营，质押期2025年6月20日至2028年10月15日。
2025-07-28Controlling shareholder Buchang (Hong Kong) pledged 6 million shares (0.54% of total) to ICBC Xishui sub-branch for operational needs; cumulative pledges reached 108.93 million shares (22.19% of its holding, 9.85% of total).控股股东步长（香港）向工商银行习水支行质押600万股（占总股本0.54%），用于经营所需；累计质押1.089亿股（占其持股22.19%，占总股本9.85%）。
2025-11-10Controlling shareholder Buchang (Hong Kong) pledged 11 million shares (1.04% of total) to China Everbright Bank Jinan Branch for operations; cumulative pledges reach 100.93 million shares (9.57% of total).控股股东步长（香港）向中国光大银行济南分行质押1100万股（占总股本1.04%），累计质押1.0093亿股（占总股本9.57%）。
2025-12-30Controlling shareholder Buchang (Hong Kong) pledged 7.6 million shares (1.55% of its holdings, 0.72% of total shares) on 2025-12-29. Cumulative pledged shares reached 108.53 million, representing 18.14% of the shareholder's holdings and 10.29% of total shares.控股股东步长（香港）于2025年12月29日质押760万股（占其持股1.55%，占总股本0.72%）。累计质押股份1.0853亿股，占其持股的18.14%，占总股本的10.29%。
2026-05-12Controlling shareholder Buchang (Hong Kong) Holdings releases a pledge of 36 million shares (no subsequent pledge).控股股东步长（香港）控股有限公司解除3600万股股份质押（不用于后续质押）。
Litigation & regulatory inquiries诉讼与监管问询
3 · 2024-05-25 → 2024-07-18
▾
Contract dispute lawsuit, SSE inquiry response, and regulatory work letter regarding media reports.合同纠纷诉讼、上交所问询回复及媒体相关监管工作函。
2024-05-25Buchang Pharma was sued for a contract dispute (承揽合同纠纷) and is scheduled to appear in court in Heze Mudan District People's Court on June 27, 2024 (case no. (2024) Lu 1702 Min Chu 5103).步长制药因承揽合同纠纷被起诉，将于2024年6月27日在菏泽市牡丹区人民法院开庭审理（案号：(2024)鲁1702民初5103号）。
2024-07-09Responded to SSE annual report inquiry, disclosing related-party purchases of liquor from Guizhou Mingshuai Wine Sales (RMB 57.33 million over 3 years) and Ningbo Guoshuai Wine Sales (RMB 10.81 million in 2023), denying improper benefit transfer.回复上交所年报问询，披露向关联方贵州名帅酒业销售有限公司（三年合计5732.56万元）及宁波国帅酒业销售有限公司（2023年1081.23万元）采购酒水，否认存在利益输送。
2024-07-18Shanghai Stock Exchange issued a regulatory work letter to Buchang Pharmaceutical regarding recent media reports.上交所就近期媒体报道相关事项向步长制药发出监管工作函。
Awards & recognitions奖项与认可
12 · 2024-06-25 → 2026-05-19
▾
Company and subsidiaries received industry awards, rankings, and recognitions for innovation, green development, and smart manufacturing.公司及子公司获得行业奖项、排名及创新、绿色发展、智能制造认可。
2024-06-25Buchang Pharma ranked first among private enterprises on the '2023 Top 100 Chinese Traditional Medicine Enterprises' list at the Misi Conference, based on R&D investment and terminal data.步长制药在米思会上荣登“2023年度中国中药企业TOP100排行榜”民营企业第一，依据研发投入和终端数据评定。
2024-07-22Subsidiaries Jilin Tiancheng Pharmaceutical and Tonghua Guhong Pharmaceutical were selected as '2024 National Private Enterprise Green Development Typical Cases' for green production process control technology innovation.子公司吉林天成制药有限公司、通化谷红制药有限公司凭借“生产过程控制绿色技术创新案例”入选“2024年度全国民营企业绿色发展典型案例”。
2024-10-12Buchang Pharma was named a founding member of the 'Traditional Chinese Medicine Respiratory Health Development Community', initiated by Guangzhou Medical University First Affiliated Hospital and others.步长制药荣列'中医药呼吸健康发展共同体'首批成员单位，该共同体由广州医科大学附属第一医院等发起。
2024-10-22Buchang Pharma was awarded '2024 Pharmaceutical Intelligent Manufacturing Demonstration Factory' and became a founding member of the 'Pharmaceutical Industry New Quality Productivity Innovation Development Community'.步长制药获评'2024药品智能制造示范工厂'，并首批加入'医药产业新质生产力创新发展共同体'。
2024-12-10Ranked on three lists at the 2024 China Traditional Chinese Medicine Brand Building Conference: '2024 Top 30 Listed TCM Companies', '2024 TCM Innovative Brand Enterprise', '2024 TCM Internationalization Promotion Brand Enterprise'.在2024中国中药品牌建设大会上荣登“2024中药上市公司30”“2024中药创新品牌企业”“2024中药国际化推进品牌企业”三大榜单。
2025-03-20Buchang subsidiary Qionglai Tianyin wins '2024 China Industry-University-Research Innovation Award' for research on Ginkgo Biloba and Mielu oral solution, including chemical characterization and quality evaluation methods.步长子公司邛崃天银制药因银杏蜜环口服溶液研究（化学物质表征、质量评价方法等）荣获“2024年中国产学研合作促进会科技创新奖-创新成果奖”。
2025-05-12Buchang Pharmaceutical was selected for JD Health's 'Double Hundred Brand Alliance' and the first Health National Brand list, partnering with JD Health on brand building and channel expansion.步长制药入选京东健康“双百品牌联盟”及首批健康国货品牌榜单，与京东健康合作进行品牌建设和渠道拓展。
2025-07-30Shandong Buchang Pharmaceutical's TCM green smart factory was recognized as a 2025 provincial advanced-level smart factory by Shandong Department of Industry and Information Technology; features 473 patents, 350-node traceability system, 30%+ income boost for 5,000+ farming households.山东步长制药中药现代化绿色智能工厂获评山东省2025年先进级智能工厂；拥有473项专利、350个节点追溯系统，带动5000余户药农年增收30%以上。
2025-08-25Buchang Pharmaceutical was listed on both the '2025 Shandong Top 200 Private Enterprises' and 'Top 100 Private Enterprises for Employment' rankings, recognized as a high-quality development benchmark in the province.步长制药入选‘2025山东民营企业200强’和‘山东民营企业吸纳就业100强’双榜单，被认定为山东省高质量发展标杆企业。
2025-11-11Shaanxi Modern Innovation Chinese Medicine Research Institute, declared by Buchang Pharma, was selected for the '2025 Shaanxi Innovation Chinese Medicine Pilot Base' support list, focusing on R&D-to-industrialization chain.由步长制药申报的“陕西省创新中药中试基地”入选2025年度择优支持名单，聚焦中药研发到产业化全链条。
2026-03-04Subsidiary Jilin Tiancheng Pharmaceutical awarded '2025 Outstanding Contribution Enterprise' for industrial economy, with net output value increase exceeding 50 million yuan.子公司吉林天成制药获评“2025年工业经济突出贡献企业”，产值净增量超5000万元。
2026-05-19Buchang is awarded 'Model Unit for 30 Years of TCM Modernization', and its products Buchang Naoxintong and Buchang Wenxin Keli are awarded 'Model Varieties for 30 Years of TCM Modernization' at the 5th TCM High-Quality Development Conference.步长制药在第五届中医药高质量发展大会上获评'中药现代化三十年示范单位'，产品步长脑心通、步长稳心颗粒获评'中药现代化三十年示范品种'。
Charitable donations慈善捐赠
3 · 2024-07-03 → 2024-11-05
▾
Donated cash and medicines to Beijing Tongxin Gongzhu Charity Foundation and other organizations.向北京同心共铸公益基金会等机构捐赠现金和药品。
2024-07-03Company and subsidiaries donated RMB 16.8 million in cash to Beijing Tongxin Gongzhu Charity Foundation for public welfare activities.公司及全资子公司向北京同心共铸公益基金会捐赠现金1680万元，用于开展公益活动。
2024-09-13Company and subsidiaries donated medicines and cash totaling RMB 37.6621 million to public welfare organizations (including RMB 36.61 million to Beijing Tongxin Gongzhu Charity Foundation).公司及子公司向公益机构捐赠药品及现金共计3766.21万元（其中向北京同心共铸公益基金会捐赠药品3661万元）。
2024-11-05Subsidiaries donated a total of 10 million yuan in cash to the Beijing Tongxin Gongzhu Charity Foundation for public welfare activities.子公司向北京同心共铸公益基金会捐赠现金共计1000万元，用于开展公益活动。
Shanghai Hepu Medical Technology license & restructuring上海合璞医疗科技许可与重组
17 · 2024-07-10 → 2026-06-10
▾
Multiple Medical Device Operating License changes, capital reductions, and subsidiary deregistrations.多次医疗器械经营许可证变更、减资及子公司注销。
2024-07-10Subsidiary Shanghai HePu Medical Technology completed the change of its Medical Device Operating License warehouse address.控股子公司上海合璞医疗科技有限公司完成医疗器械经营许可证库房地址变更登记。
2024-09-11Controlled subsidiary Shanghai HePu Medical Technology completed change of Medical Device Operating License (warehouse address).控股子公司上海合璞医疗科技有限公司完成医疗器械经营许可证变更（库房地址）。
2024-12-26Agreed to waive preemptive right in controlled subsidiary Shanghai He Pu; shareholder Wang Baocai transfers 0.05% and 0.025% unpaid equity at zero price to Zhao Xiaogang and Cheng Kai; Buchang's stake remains 71.30%.放弃控股子公司上海合璞优先受让权，股东王宝才将未实缴的0.05%和0.025%股权以0元转让给赵晓刚和程锴，步长持股仍为71.30%。
2025-03-18Subsidiary Shanghai Hepu Medical Tech to invest RMB 1.4M (70%) with Suzhou Mingpu Medical Tech (RMB 0.6M, 30%) to set up Suzhou Hepu Medical Devices Co., Ltd. (RMB 2M registered capital).控股子公司上海合璞医疗科技拟与苏州工业园区明普医疗科技共同投资设立苏州合璞医疗器械有限公司（注册资本200万元），上海合璞出资140万元（70%）。
2025-05-27Controlling subsidiary Shanghai Hepu Medical Technology completed changes to its Medical Device Operating License, mainly adjusting warehouse addresses.控股子公司上海合璞医疗科技有限公司完成医疗器械经营许可证变更，主要涉及库房地址调整。
2025-05-28Controlling subsidiary Shanghai Hepu Medical Technology completed business scope industrial and commercial change, adding technical services, medical device leasing, import/export, etc.控股子公司上海合璞医疗科技有限公司完成经营范围工商变更，新增技术服务、医疗器械租赁、进出口业务等。
2025-06-24Controlling subsidiary Shanghai Hepu Medical Technology will reduce capital of its wholly-owned subsidiaries Beijing Hepu Jingyuan (from 10M to 2M yuan) and Jiangsu Hepu Medical (from 50.2M to 2M yuan).控股子公司上海合璞医疗科技拟对全资子公司北京合璞景源（注册资本由1000万减至200万）和江苏合璞医疗（由5020万减至200万）进行减资。
2025-07-04Subsidiary Shanghai Hepu Medical Devices obtained updated Medical Device Operating License, changing warehouse address and expanding scope to include Class III devices and in-vitro diagnostics.控股子公司上海合璞医疗器械取得更新后的《医疗器械经营许可证》，变更库房地址并扩大经营范围，涵盖三类医疗器械及体外诊断试剂。
2025-09-05Buchang Pharma's subsidiary Shanghai Hepu reduced capital in its wholly-owned subsidiary Jiangsu Hepu, cutting registered capital from 50.2 million yuan to 5 million yuan.步长制药控股子公司上海合璞对其全资子公司江苏合璞减资，注册资本从5020万元降至500万元。
2025-09-05Buchang Pharma's subsidiary Beijing Hepu Jingyuan Medical Technology completed business registration with registered capital of 2 million yuan.步长制药控股子公司北京合璞景源医疗科技有限公司完成工商变更登记，注册资本200万元。
2025-11-25Buchang Pharma's controlled subsidiary Shanghai Hepu Medical Technology obtained a renewed Medical Device Operating License, adding in-vitro diagnostic reagents (cold-chain storage) and expanding warehouse locations to Nanning and Nanchang.步长制药控股子公司上海合璞医疗科技换发《医疗器械经营许可证》，新增体外诊断试剂（需低温冷藏）经营范围，并扩展南宁、南昌库房地址。
2025-12-29Controlled subsidiary Shanghai Hepu filed a lawsuit against Zimmer (Shanghai) Medical International Trading Co., Ltd. for contract dispute, involving approximately RMB 652M. Claim includes buyback of ~RMB 556M remaining inventory, refund of ~RMB 3.2M prepayment, and interest losses. Case accepted by Shanghai First Intermediate People's Court, not yet tried.控股子公司上海合璞因合同纠纷起诉捷迈（上海）医疗国际贸易有限公司，涉案金额约6.52亿元，要求回购约5.56亿元剩余库存、退还约320万元预付款及利息损失。上海市第一中级人民法院已立案，尚未开庭。
2026-01-12Controlling subsidiary Shanghai He Pu filed a lawsuit against Zimmer (Shanghai) Medical International Trading over expired distribution agreement, involving inventory of about 550 million yuan and total claim of 652 million yuan.控股子公司上海合璞因经销协议期满后的库存纠纷起诉捷迈（上海）医疗国际贸易有限公司，涉及约5.5亿元库存，总索赔金额6.52亿元。
2026-04-03Subsidiary Shanghai Hepu Medical Technology completed change of Medical Device Operating License (warehouse address change).控股子公司上海合璞医疗科技有限公司完成医疗器械经营许可证变更（库房地址变更）。
2026-05-14Controlling subsidiary Shanghai Hepu Medical Technology plans to invest 3.15 million yuan (70%) to jointly set up Sichuan Hepu Tongchuang Medical Technology Co., Ltd. with Sichuan Lindong Enterprise Management Center (1.35 million yuan, 30%), registered capital 4.5 million yuan, to expand medical device business.控股子公司上海合璞医疗科技拟出资315万元（70%）与四川霖东企业管理中心（135万元，30%）共同设立四川合璞同创医疗科技有限公司，注册资本450万元，拓展医疗器械业务。
2026-06-03New subsidiary Sichuan Hepu Tongchuang Medical Technology established, held by Buchang's Shanghai Hepu Medical Technology, engaged in medical device sales.新设子公司四川合璞同创医疗科技有限公司，由步长旗下上海合璞医疗科技有限公司持股，从事医疗器械销售。
2026-06-10Controlling subsidiary Shanghai Hepu Medical Equipment completes Medical Device Operation License change, relocating from Fengxian to Xuhui District, Shanghai.控股子公司上海合璞医疗器械有限公司完成《医疗器械经营许可证》变更，住所及经营场所从上海奉贤区迁至徐汇区。
Wenxin Granule (稳心颗粒) overseas registration稳心颗粒海外注册
2 · 2024-07-25 → 2024-08-02
▾
Wenxin Granules obtained drug registration approval in Malaysia.稳心颗粒获得马来西亚药品注册批准。
2024-07-25Product Wenxin Granules (ZBT Wenxin Granules) received drug registration approval from Malaysia's Drug Control Authority, valid until August 2, 2029, meeting Malaysian traditional Chinese medicine registration standards.产品稳心颗粒（ZBT稳心颗粒）获得马来西亚药物管制局药品注册批准，有效期至2029年8月2日，符合马来西亚传统中药注册标准。
2024-08-02Buchang Pharma's product Wenxin Granule (稳心颗粒) received drug registration approval from the Malaysian Drug Control Authority, meeting Malaysia's traditional Chinese medicine registration standards, marking a step into the international market.步长制药产品稳心颗粒获得马来西亚药物管制局药品注册批准，符合马来西亚传统中药注册标准，标志着开拓国际市场。
Executive & governance changes高管与治理变更
7 · 2024-07-30 → 2026-04-01
▾
Board elections, supervisory board changes, director nominations, and executive resignations.董事会选举、监事会变更、董事提名及高管辞职。
2024-07-30Board elected Zhao Tao as Chairman and legal representative, Wang Yimin and Zhao Jing as Vice Chairmen at the 5th Board's 1st meeting.第五届董事会第一次会议选举赵涛为董事长及法定代表人，王益民、赵菁为副董事长。
2024-07-30Supervisory board elected Wang Minggeng as Chairman of the 5th Supervisory Board.监事会选举王明耿为第五届监事会主席。
2025-05-26Vice President Wang Baocai resigned due to personal reasons, effective upon delivery of resignation letter; he will hold no further positions in the company.副总裁王宝才因个人原因辞职，辞职报告送达董事会时生效，辞职后不再担任公司任何职务。
2025-10-17Director Zhao Chao resigned as non-independent director and member of the Strategy & Investment Committee due to personal reasons, but remains as President.董事赵超因个人原因辞去非独立董事及战略与投资委员会委员职务，但仍担任总裁。
2025-10-29Board nominated Wang Minggeng and Lei Yalin as non-independent director candidates, and Song Xiayun and Chen Zhanming as independent director candidates, to fill vacancies.董事会提名王明耿、雷雅麟为非独立董事候选人，宋夏云、陈占明为独立董事候选人，以填补空缺。
2025-11-26Buchang Pharma Vice Chairperson Zhao Jing was re-elected as a standing council member of the China Glory Society at its 7th member congress.步长制药副董事长赵菁在中国光彩事业促进会第七次会员代表大会上连任常务理事。
2026-04-01Chairman Zhao Tao was appointed Honorary Chairman of the Hong Kong-Mainland International Investment Society for a five-year term starting March 30, 2026.董事长赵涛获聘香港国际投资总会名誉主席，任期五年，自2026年3月30日起。
Dividends & share repurchase分红与股份回购
4 · 2024-08-12 → 2025-09-05
▾
Announcement of cash dividend plans, interim dividends, and profit distribution decisions.现金分红方案、中期分红及利润分配决策公告。
2024-08-12Buchang Pharma announced the 2023 annual cash dividend plan: distributing CNY 1.26 (pre-tax) per 10 shares, with a total payout of approximately CNY 135.62 million, record date August 19, ex-dividend date August 20, 2024.步长制药公布2023年年度权益分派方案：每10股派发现金红利1.26元（含税），合计派发现金红利约1.36亿元，股权登记日2024年8月19日，除权除息日2024年8月20日。
2025-04-25Buchang Pharma announced 2024 annual profit distribution plan: no cash dividend, no bonus shares, no capital reserve increase, due to negative net profit and planned cancellation of repurchased shares (total repurchase amount RMB 710.53 million in 2024).步长制药公布2024年度利润分配预案：不派发现金红利、不送红股、不转增股本，因净利润为负及拟注销已回购股份（2024年回购总额7.11亿元）。
2025-05-26Board approved a 2025 interim dividend arrangement, with total payout not exceeding net profit attributable to shareholders for the corresponding period, subject to shareholder meeting approval.董事会审议通过2025年中期分红安排，分红总额不超过相应期间归属于上市公司股东的净利润，尚需股东大会批准。
2025-09-05Buchang Pharma proposed a 2025 interim dividend of 3.9 yuan per 10 shares (tax included), totaling approximately 411 million yuan.步长制药拟2025年中期每10股派发现金红利3.9元（含税），合计约4.11亿元。
Angong Niuhuang Pill (安宫牛黄丸) technology acquisition & launch安宫牛黄丸技术收购与上市
4 · 2024-08-20 → 2025-05-27
▾
Acquired production technology from Liaoning Hancaotang; obtained marketing authorization transfer; product launched.从辽宁汉草堂收购生产技术；获得上市许可持有人变更；产品上市销售。
2024-08-20Buchang Pharma disclosed it had agreed to acquire the production technology for Angong Niuhuang Pill (安宫牛黄丸) from Liaoning Hancao Tang Chinese Medicine Co., Ltd. for CNY 8.4 million, with the technology transfer contract signed in April 2023.步长制药披露拟以840万元受让辽宁汉草堂中药有限公司拥有的安宫牛黄丸药品生产技术，相关技术合同已于2023年4月签署。
2025-01-21Obtained Shandong Provincial Drug Administration approval to amend Drug Manufacturing License: added entrusted production of An Gong Niu Huang Wan (by Liaoning Hancaotang) and Montelukast Sodium Chewable Tablets (by Shandong Danhong), classification code changed to AhzBzCh.获山东省药监局许可变更《药品生产许可证》，增加委托生产安宫牛黄丸（受托方辽宁汉草堂）和孟鲁司特钠咀嚼片（受托方山东丹红），分类码变更为AhzBzCh。
2025-03-18Buchang Pharma receives NMPA approval to transfer marketing authorization holder of Angong Niuhuang Pill from Liaoning Hancaotang to Buchang Pharma.步长制药收到国家药监局同意将安宫牛黄丸的上市许可持有人由辽宁汉草堂变更为步长制药的批准通知书。
2025-05-27Company confirmed that An Gong Niu Huang Wan (Angong Niuhuang Pill) received the Drug Supplementary Application Approval Notice on March 12, 2025, and is available for sale.公司确认安宫牛黄丸已于2025年3月12日获得《药品补充申请批准通知书》，可上市销售。
Shaanxi Buchang Pharmaceutical production & smart factory陕西步长制药生产与智能工厂
9 · 2024-08-28 → 2026-04-30
▾
Production license amendments, smart factory awards, and solar power project at Shaanxi Buchang.陕西步长生产许可变更、智能工厂奖项及光伏发电项目。
2024-08-28Buchang Pharma's wholly-owned subsidiary Shaanxi Buchang Pharmaceutical received approval from Shaanxi Medical Products Administration to amend its Drug Manufacturing License, adding production addresses, workshop lines, entrusted production varieties, and changing the classification code.步长制药全资子公司陕西步长制药获得陕西省药品监督管理局许可，同意其《药品生产许可证》增加生产地址及车间生产线、增加受托生产品种、分类码变更。
2024-09-09Subsidiary Shaanxi Buchang passed GMP inspection for seabuckthorn fruit oil extraction line (annual capacity 13,750 kg) and soft capsule line (annual capacity 200 million pills).子公司陕西步长沙棘果油前处理提取线（年产能13,750千克）及软胶囊剂生产线（年产能2亿丸）通过GMP符合性检查。
2025-05-10Subsidiary Shaanxi Buchang's 2.071 MW rooftop distributed photovoltaic power generation project was completed and connected to the grid, expected to generate 3 million kWh annually.子公司陕西步长制药有限公司的2.071兆瓦屋顶分布式光伏发电项目竣工并网，预计年发电量300万千瓦时。
2025-06-06Wholly-owned subsidiary Shaanxi Buchang obtained approval to add 'tea preparation' to its drug production license scope, valid until Dec 16, 2025.全资子公司陕西步长获陕西省药监局批准，在《药品生产许可证》生产范围中增加“茶剂”，有效期至2025年12月16日。
2025-06-25Subsidiary Shaanxi Buchang was selected into Shaanxi Province's 2025 first batch of advanced-level smart factory list.子公司陕西步长入选陕西省2025年度第一批先进级智能工厂名单。
2025-07-15Subsidiary Shaanxi Buchang Pharmaceutical was selected as a 2025 first-batch advanced-level smart factory by Shaanxi Provincial Department of Industry and Information Technology for intelligent manufacturing in TCM.子公司陕西步长制药入选陕西省工信厅2025年度第一批先进级智能工厂名单，因其中药智能制造表现。
2025-11-27Buchang Pharma's wholly-owned subsidiary Shaanxi Buchang received Shaanxi Medical Products Administration approval to add a tablet production line at its Xianyang plant and switch sitagliptin phosphate tablet production from entrusted to in-house, passing GMP inspection.步长制药全资子公司陕西步长获陕西省药监局许可，在咸阳厂区新增片剂生产线，并将磷酸西格列汀片由受托生产转为自行生产，通过GMP符合性检查。
2026-01-21Subsidiary Shaanxi Buchang Pharmaceutical was selected into Shaanxi Province 2025 Advanced-level Smart Factory Benchmarking Project list.子公司陕西步长制药入选陕西省2025年先进级智能工厂标杆项目名单。
2026-04-30Subsidiary Shaanxi Buchang Pharmaceutical QC team awarded 2026 National Worker Pioneer and National May Day Women's Pacesetter titles.子公司陕西步长制药有限公司质量控制部QC班组荣获2026年全国工人先锋号及全国五一巾帼标兵岗称号。
Yangling Buchang production & GMP杨凌步长生产与GMP
6 · 2024-09-03 → 2026-06-09
▾
GMP inspection for chemical drug workshop and seabuckthorn oil line; production license extensions and scope changes.化药车间和沙棘油生产线通过GMP检查；生产许可延期及范围变更。
2024-09-03Subsidiary Yangling Buchang passed GMP inspection for its chemical drug workshop (designed capacity 336.875 million tablets/year) producing tadalafil tablets.子公司杨凌步长他达拉非片化药车间（设计产能3.36875亿片/年）通过GMP符合性检查。
2024-11-13Wholly-owned subsidiary Yangling Buchang obtained drug production license amendment from Shaanxi MPA, adding entrusted production of Kechuan'an Oral Liquid.全资子公司杨凌步长获陕西省药监局药品生产许可证变更，增加受托生产品种咳喘安口服液。
2025-02-19Wholly-owned subsidiary Yangling Buchang obtained Shaanxi Medical Products Administration approval to extend its Drug Manufacturing License validity to Feb 6, 2030, and adjust entrusted production periods for Vancomycin HCl capsules, Tadalafil tablets, and Calcium carbonate chewable tablets.全资子公司杨凌步长获得陕西省药监局许可，将《药品生产许可证》有效期延至2030年2月6日，并调整盐酸万古霉素胶囊、他达拉非片、碳酸钙咀嚼片等药品的委托生产期限。
2025-11-07Buchang Pharma's wholly-owned subsidiary Yangling Buchang changed its business scope to add 'solar power technology services'; its net assets were -113 million yuan as of Sept 2025, with a net loss of 28.8953 million yuan in first three quarters.步长制药全资子公司杨凌步长经营范围变更，新增“太阳能发电技术服务”；截至2025年9月末净资产为-1.13亿元，前三季度净亏损2889.53万元。
2025-12-01Wholly-owned subsidiary Yangling Buchang completed industrial and commercial registration for business scope change, adding items including TCM extract production, medical research, solar power technology services, and drug import/export.全资子公司杨凌步长完成工商变更登记，经营范围新增中药提取物生产、医学研究、太阳能发电技术服务及药品进出口等项目。
2026-06-09Subsidiary Yangling Buchang changes business scope to add special medical purpose formula food (FSMP) sales and production.全资子公司杨凌步长变更经营范围，新增特殊医学用途配方食品销售与生产业务。
Efparepoetin alfa (rhEPO-Fc) NDA & overseas dealsEfparepoetin alfa（rhEPO-Fc）上市申请与海外交易
6 · 2024-09-04 → 2026-05-19
▾
NDA accepted for CKD anemia drug; exclusive supply agreements signed with Philippines, Vietnam, and Malaysia.慢性肾病贫血药物上市申请获受理；与菲律宾、越南、马来西亚签署独家供应协议。
2024-09-04Controlled subsidiary Sichuan Luzhou Buchang Biopharm's NDA for 'Epoetin Alfa Injection' (rhEPO-Fc, for CKD anemia in dialysis patients) was accepted by NMPA; no similar product approved in China.控股子公司四川泸州步长生物的“注射用艾帕依泊汀α”（rhEPO-Fc，用于透析患者慢性肾病贫血）上市申请获国家药监局受理，国内尚无同类品种获批。
2025-08-07Controlled subsidiary Luzhou Buchang signed an exclusive supply agreement with Philippine company GOODFELLOW for injectable Efparepoetin alfa (Class I new biological drug for CKD anemia), granting exclusive agency for registration, clinical trials, promotion, distribution and sales in the Philippines.控股子公司泸州步长与菲律宾公司GOODFELLOW签署独家供应协议，授权其在菲律宾独家代理注射用依派促红素α（治疗慢性肾病贫血的I类生物新药）的注册、临床试验、推广、分销及销售。
2025-10-29Controlled subsidiary Luzhou Buchang signed Distribution, Marketing Services and Agency Agreement with Helios (Vietnam) and Good Morning International for exclusive marketing and distribution of Efparepoetin alfa for injection (Class 1 biologic new drug, NDA submitted) in Vietnam.控股子公司泸州步长与越南Helios、早安国际签署协议，授权在越南独家营销和经销注射用依派促红素α（治疗用生物制品I类新药，已提交上市申请）。
2025-12-29Controlled subsidiary Luzhou Buchang signed an Exclusive Supply Agreement with Malaysian company MEDISPEC (M) SDN BHD, appointing MEDISPEC as the exclusive agent in Malaysia for registration, promotion, distribution and sales of injection Efparepoetin alfa (a recombinant fusion protein for anemia in chronic kidney disease, a Class 1 new biologic). Exclusive period: 10 years from import license, renewable for 5 years.控股子公司泸州步长与马来西亚公司MEDISPEC签署《独家供应协议》，授权MEDISPEC作为马来西亚独家代理商，负责注射用Efparepoetin alfa（治疗慢性肾病贫血的I类生物新药）的注册、推广、分销和销售，独家期限为获得进口许可之日起10年，可续期5年。
2026-01-06Controlling subsidiary Luzhou Buchang signed an exclusive supply agreement with Malaysia's MEDISPEC (M) SDN BHD for the registration, promotion, distribution and sale of injection Efparepoetin alfa in Malaysia.控股子公司泸州步长与马来西亚MEDISPEC公司签署独家供应协议，授权其在马来西亚注册、推广、分销及销售注射用Efparepoetin alfa。
2026-05-19In an investor Q&A, Buchang discloses that its Class 1 new drug 'Efparepoetin alfa' (for CKD anemia in dialysis patients) is under NMPA review for marketing approval, and that Luzhou Buchang has signed exclusive supply/distribution agreements with companies in the Philippines, Vietnam, and Malaysia.步长制药在互动平台披露，I类新药'依派促红素α'（用于透析患者CKD贫血）处于上市审评审批中，泸州步长已与菲律宾、越南、马来西亚等国企业签署独家供应及经销协议。
Subsidiary dissolution & deregistration子公司解散与注销
5 · 2024-10-17 → 2026-02-26
▾
Dissolution or deregistration of subsidiaries and associates to optimize resources.为优化资源配置而解散或注销子公司及联营公司。
2024-10-17Buchang Pharma decided to dissolve its subsidiary Shangzhi Buchang Biomedical Technology Co., Ltd., which had net assets of -77,700 yuan and zero revenue as of June 2024.步长制药决定注销子公司尚志市步长生物医疗科技有限公司，截至2024年6月净资产-7.77万元，营收为零。
2025-02-07Wholly-owned subsidiary Meihekou Tianyu Pharmaceutical Sales Co., Ltd. was deregistered to optimize resource allocation and reduce management costs.全资子公司梅河口天宇医药销售有限公司完成注销，以优化资源配置、降低管理成本。
2025-02-10Associate Beijing Kuaifang Technology Co., Ltd. completed deregistration; the company held 11.538% stake, and the move will not affect consolidated financials.参股公司北京快方科技有限公司完成注销；公司持股11.538%，该注销不会影响合并报表。
2025-11-27Buchang Pharma's controlled subsidiary Changrui Biotechnology's investee Chengdu Guosheng Biomedical Technology completed its industrial and commercial deregistration; Changrui held 15% equity.步长制药控股子公司长睿生物的参股公司成都国生生物医药科技有限公司完成工商注销登记，长睿生物持股15%。
2026-02-26Buchang Pharmaceutical failed to win the restructuring investor qualification auction for Wuhu Rentang Pharmaceutical Co., Ltd., a move to expand its TCM segment layout.步长制药未能竞得芜湖仁德堂药业有限公司重整投资人资格，该举措旨在拓展其中药细分领域布局。
Baoding Tianhao drug approvals & clinical trials保定天浩药品批准与临床试验
11 · 2024-11-13 → 2026-06-08
▾
Received drug registration certificates for Donepezil, Oseltamivir; clinical trial approvals for Compound Sodium Sulfate Tablets and BC003.获得多奈哌齐、奥司他韦药品注册证书；复方硫酸钠片和BC003临床试验批准。
2024-11-13Wholly-owned subsidiary Baoding Tianhao received NMPA acceptance for clinical trial application of Compound Sodium Sulfate Tablets (chemical class 3) for colon cleansing before colonoscopy; R&D cost ~2.14 million yuan.全资子公司保定天浩的复方硫酸钠片（化药3类）获国家药监局临床试验申请受理，用于肠镜检查前结肠清洁；研发费用约214.39万元。
2024-12-03Wholly-owned subsidiary Baoding Tianhao Pharmaceutical received Drug Registration Certificate for Donepezil Hydrochloride Tablets (5mg), for Alzheimer's disease, deemed passing consistency evaluation.全资子公司保定天浩制药获得盐酸多奈哌齐片（5mg）《药品注册证书》，用于阿尔茨海默病，视同通过一致性评价。
2025-01-02Subsidiary Baoding Tianhao signed a supplemental agreement with Zhengzhou Shenlanhai Biomedical for Phase II clinical study of BC003 and Xinhuosu (Neo-Sivelestat) in acute decompensated heart failure, adding 90 patients and 20 centers at CNY 8.37 million total.全资子公司保定天浩与郑州深蓝海生物医药签署补充协议，新增BC003和新活素治疗急性失代偿性心力衰竭的II期临床研究，增加90例受试者、20家中心，总费用837万元。
2025-01-09Subsidiary Baoding Tianhao received NMPA drug registration certificate for Oseltamivir Phosphate for Oral Suspension (0.36g, Category 3 chemical drug) for influenza A/B treatment and prevention; R&D cost ~CNY 14.42 million.全资子公司保定天浩获国家药监局磷酸奥司他韦干混悬剂（0.36g，化药3类）药品注册证书，用于甲型和乙型流感治疗和预防，研发投入约1441.83万元。
2025-01-23Subsidiary Baoding Tianhao obtained Hebei Drug Administration approval to add production address and scope, and change production responsible person on its Drug Manufacturing License.全资子公司保定天浩获河北省药监局许可，增加生产地址和生产范围、变更生产负责人。
2025-02-10Wholly-owned subsidiary Baoding Tianhao received NMPA clinical trial approval for Compound Sodium Sulfate Tablets (chemical class 3) for adult colonoscopy bowel preparation; R&D investment of RMB 4.2608 million as of Jan 31, 2025.全资子公司保定天浩获得国家药监局关于复方硫酸钠片（化药3类）的临床试验批准，用于成人肠镜检查前结肠清洁；截至2025年1月31日研发投入426.08万元。
2025-05-06Wholly-owned subsidiary Baoding Tianhao Pharmaceutical passed the re-identification of High-tech Enterprise, valid for 3 years (2024-2026), enjoying a 15% corporate income tax rate.全资子公司保定天浩制药有限公司通过高新技术企业重新认定，有效期三年（2024-2026年），享受15%企业所得税优惠税率。
2025-08-14Wholly-owned subsidiary Baoding Tianhao obtained approval from Hebei Medical Products Administration to update production scope on its Drug Manufacturing License, adding specific entrusted production items including Oseltamivir Phosphate for Suspension, Donepezil Hydrochloride Tablets, and Sitagliptin-Metformin ER Tablets.全资子公司保定天浩获得河北省药监局批准，更新《药品生产许可证》生产范围，新增磷酸奥司他韦干混悬剂、盐酸多奈哌齐片、西格列汀二甲双胍缓释片等委托生产品种。
2025-11-24Buchang Pharma's subsidiary Baoding Tianhao passed the 6th intellectual property management system surveillance audit, having obtained 2 invention patents, 7 utility model patents, and 3 design patents since 2020.步长制药子公司保定天浩通过第6次知识产权管理体系监督审核，自2020年以来获发明专利2件、实用新型专利7件、外观设计专利3件。
2025-12-01Subsidiary Baoding Tianhao received approval from Hebei Medical Products Administration to change its Drug Manufacturing License, adding a soft capsule workshop and oral solution production line at Shaanxi Buchang site for Vitamin D3 drops (400 IU and 800 IU), with entrusted production valid until 2030-07-07 for registration use only.子公司保定天浩获河北省药监局批准变更《药品生产许可证》，在陕西步长厂区新增软胶囊车间及口服溶液剂生产线，用于生产维生素D滴剂（400单位和800单位），委托有效期至2030年7月7日，仅限注册申报使用。
2026-06-08Subsidiary Baoding Tianhao obtained updated Drug Manufacturing License from Hebei MPA, adding a tablet production line for Calcium Carbonate D3 Tablets (I) at Yangling Buchang site, for registration use only.子公司保定天浩取得河北省药监局换发的《药品生产许可证》，新增杨凌步长厂区化药车间二的片剂生产线（碳酸钙D3片（I）），仅限注册申报使用。
GMP & regulatory complianceGMP与监管合规
5 · 2024-11-27 → 2025-09-08
▾
Subsidiaries passed GMP inspections, received pharmacovigilance base designations, and obtained drug manufacturing license changes.子公司通过GMP检查、获选药物警戒基地、药品生产许可证变更。
2024-11-27Buchang Pharma and subsidiary Shandong Danhong selected as first batch of drug警戒 standardization practice bases by Shandong MPA.步长制药及子公司山东丹红入选山东省首批药品上市许可持有人药物警戒规范化实践基地。
2024-11-29Wholly-owned subsidiary Tonghua Guhong passed GMP compliance inspection for small-volume injection lines (Doxofylline Injection, Ambroxol Hydrochloride Injection); design capacity 120 million units.全资子公司通化谷红通过小容量注射剂生产线（多索茶碱注射液、盐酸氨溴索注射液）GMP符合性检查，设计产能1.2亿支。
2024-12-01Wholly-owned subsidiary Tonghua Guhong Pharmaceutical passed GMP compliance inspection by Jilin Provincial Drug Administration and received the certificate.全资子公司通化谷红制药通过吉林省药品监督管理局的GMP符合性检查并获得通知书。
2024-12-10Shandong Buchang Pharmaceutical and its subsidiary Shandong Danhong Pharmaceutical were selected as one of the first batch of 10 drug-holder pharmacovigilance standardized practice bases in Shandong Province.山东步长制药及其子公司山东丹红制药入选山东省首批10个药品上市许可持有人药物警戒规范化实践基地。
2025-09-08Buchang Pharma obtained Shandong FDA approval to add entrusted production of Xiaolin Baidu Powder at Shandong Kongfu Pharmaceutical (Qufu) under its Drug Production License, valid until May 2028.步长制药获山东省药监局许可，在《药品生产许可证》副本增加委托生产，受托方为山东孔府制药（曲阜），生产品种为消淋败毒散，有效期至2028年5月。
Buchang (Guangzhou) Medical Diagnostics capital reduction & dissolution步长（广州）医学诊断减资与解散
7 · 2024-11-28 → 2026-05-13
▾
Reduced registered capital multiple times; board approved dissolution to optimize resources.多次减少注册资本；董事会批准解散以优化资源配置。
2024-11-28Controlling subsidiary Buchang (Guangzhou) Medical Diagnostics reduced registered capital from 58.8235 million yuan to 11.8682 million yuan to optimize resources.控股子公司步长（广州）医学诊断技术有限公司注册资本由5882.3529万元减少至1186.8245万元，以优化资源配置。
2024-12-01Controlled subsidiary Buchang (Guangzhou) Medical Diagnostics reduced registered capital from 58.82 million yuan to 11.87 million yuan, with Buchang's stake changing from 70.8% to 70.3%.控股子公司步长（广州）医学诊断技术有限公司注册资本从5882万元减至1187万元，步长持股比例从70.8%变为70.3%。
2025-06-17Controlling subsidiary Buchang (Guangzhou) Medical Diagnostics signed a capital reduction agreement, reducing registered capital from 58.8235 million yuan to 11.8682 million yuan (79.83% reduction) at zero consideration.控股子公司步长（广州）医学诊断技术有限公司签署《减资协议》，注册资本由5882.35万元减至1186.82万元（减资79.83%），减资对价为0元。
2025-07-18Subsidiary Buchang (Guangzhou) Medical Diagnostics completed capital reduction from 58.8235 million yuan to 11.8682 million yuan (79.83% reduction); Buchang Pharma's stake rose to 70.33%.控股子公司步长（广州）医学诊断技术完成减资，注册资本由5882.35万元减至1186.82万元（减幅79.83%）；步长制药持股比例升至70.33%。
2025-09-05Buchang Pharma's board approved the dissolution of Buchang (Guangzhou) Medical Diagnostics Technology Co., Ltd. to optimize resource allocation and reduce management costs.步长制药董事会批准注销步长（广州）医学诊断技术有限公司，以优化资源配置、降低管理成本。
2026-03-12Controlling subsidiary Buchang (Guangzhou) Medical Diagnostics to transfer 60% equity in Hunan Zhongce to Yang Futai for RMB 1, exiting the investment as the target has negative net assets of -450,000 yuan.控股子公司步长（广州）医学诊断以1元转让湖南众测60%股权给杨福太，标的净资产为-45万元，退出该投资。
2026-05-13Controlling subsidiary Buchang (Guangzhou) Medical Diagnostics completes the 1-yuan sale of its 60% stake in Hunan Zhongce Bio to Yang Futai, exiting the IVD business to optimize asset structure.控股子公司步长（广州）医学诊断以1元价格向杨福太转让湖南众测生物60%股权，已完成工商变更，退出体外诊断业务以优化资产结构。
Shenfu Yixin Granules (参附益心颗粒) clinical trial参附益心颗粒临床试验
3 · 2024-12-03 → 2025-11-27
▾
Signed clinical trial entrustment contract for registration; contract restructured to Shandong Danhong.签署注册临床试验委托合同；合同转至山东丹红。
2024-12-03Signed a clinical trial entrustment contract with Beijing Zhuoyue Future International Medical Technology Development for Shenfu Yixin Granules registration, total fee 55.338 million yuan (tax incl.).与北京卓越未来国际医药科技发展有限公司签订《参附益心颗粒注册临床试验委托合同》，总费用5533.8万元（含税）。
2025-11-26Buchang Pharma and its subsidiary Shandong Danhong signed a supplementary agreement with Beijing Zhuoyue Future to transfer the rights and obligations of the 'Shenfu Yixin Granules' clinical trial contract to Shandong Danhong, with an upfront payment of 16.6014 million yuan to be refunded.步长制药及子公司山东丹红与北京卓越未来签订补充协议，将参附益心颗粒临床试验合同的权利义务转移至山东丹红，已支付的1660.14万元首期款将退还。
2025-11-27Buchang Pharma's wholly-owned subsidiary Shandong Danhong signed a 60.338 million yuan (tax incl.) clinical trial entrustment contract with Beijing Zhuoyue Future for the registration trial of 'Shenfu Yixin Granules' (参附益心颗粒), covering 480 cases.步长制药全资子公司山东丹红与北京卓越未来签订6033.8万元（含税）的参附益心颗粒注册临床试验委托合同，涉及480例病例。
Varicella & influenza vaccines (Zhejiang Tianyuan)水痘与流感疫苗（浙江天元）
12 · 2024-12-17 → 2026-05-14
▾
Varicella live vaccine clinical trial approved; quadrivalent influenza vaccine approved; rabies vaccine trial withdrawn.水痘减毒活疫苗临床试验获批；四价流感疫苗获批；狂犬疫苗试验撤回。
2024-12-17Controlled subsidiary Zhejiang Tianyuan Bio-Pharmaceutical's clinical trial application for Varicella Attenuated Live Vaccine was accepted by the National Medical Products Administration; R&D investment about 26.9365 million yuan.控股子公司浙江天元生物药业的“水痘减毒活疫苗”药品注册临床试验申请获国家药监局受理，研发费用约2693.65万元。
2025-01-03Subsidiary Zhejiang Tianyuan Bio's varicella attenuated live vaccine clinical trial application accepted by NMPA; R&D investment of about CNY 26.94 million as of Nov 2024.控股子公司浙江天元生物的“水痘减毒活疫苗”临床试验申请获国家药监局受理，截至2024年11月底研发投入约2693.65万元。
2025-03-12Subsidiary Zhejiang Tianyuan Bio receives NMPA clinical trial approval for varicella attenuated live vaccine; R&D investment ~RMB 28.55M.控股子公司浙江天元生物收到国家药监局关于水痘减毒活疫苗的《药物临床试验批准通知书》；研发投入约2854.60万元。
2025-03-12Subsidiary Zhejiang Tianyuan Bio's clinical trial application for freeze-dried rabies vaccine (human diploid cell) is accepted by NMPA.控股子公司浙江天元生物的冻干人用狂犬病疫苗（人二倍体细胞）药品注册临床试验申请获国家药监局受理。
2025-04-01Buchang Pharma disclosed that its subsidiary Zhejiang Tianyuan Biological's varicella live attenuated vaccine received clinical trial approval from the NMPA; subsidiary Baoding Tianhao's compound sodium sulfate tablets for colonoscopy preparation received clinical trial approval (R&D cost RMB 4.26 million); and Baoding Tianhao's oseltamivir phosphate dry suspension obtained drug registration certificate for influenza prevention in ages 1+.步长制药披露，子公司浙江天元生物的‘水痘减毒活疫苗’获国家药监局临床试验批准；保定天浩的‘复方硫酸钠片’获临床试验批准（研发投入426万元）；‘磷酸奥司他韦干混悬剂’获药品注册证书，用于1岁以上人群流感预防。
2025-06-03Controlling subsidiary Zhejiang Tianyuan voluntarily withdrew the clinical trial registration application for freeze-dried human rabies vaccine (human diploid cell) after NMPA review required further research; R&D cost invested ~52.62 million yuan as of May 29, 2025.控股子公司浙江天元主动撤回冻干人用狂犬病疫苗（人二倍体细胞）的注册临床试验申请，因药审中心要求完善研究；截至2025年5月29日研发投入约5262万元。
2025-07-11Subsidiary Zhejiang Tianyuan Bio-pharmaceutical received NMPA Drug Registration Certificate for Quadrivalent Influenza Virus Split Vaccine (specification 0.5ml pre-filled syringe); cumulative R&D investment approx. 125.8262 million yuan.控股子公司浙江天元生物药业获得国家药监局四价流感病毒裂解疫苗（0.5ml预灌封注射剂）药品注册证书；累计研发投入约1.26亿元。
2025-09-08Buchang Pharma's subsidiary Zhejiang Tianyuan Bio received NMPA Drug Registration Certificate for quadrivalent influenza virus split vaccine (injection, 0.5ml/dose) in July 2025, adding to its 6-vaccine portfolio; varicella, herpes zoster, and rabies vaccines are under development.步长制药控股子公司浙江天元生物于2025年7月获国家药监局四价流感病毒裂解疫苗（注射剂，0.5ml/剂）《药品注册证书》，疫苗产品增至6项；水痘、带状疱疹、狂犬病疫苗在研。
2026-02-27Subsidiary Zhejiang Tianyuan Bio-Pharmaceutical's clinical trial application for quadrivalent influenza virus split vaccine was accepted by the National Medical Products Administration (NMPA).控股子公司浙江天元生物药业的四价流感病毒裂解疫苗临床试验申请获国家药监局受理。
2026-03-04Subsidiary Zhejiang Tianyuan Bio-Pharmaceutical's quadrivalent influenza virus split vaccine clinical trial application accepted by NMPA; subsidiary's Clindamycin Hydrochloride Capsule passes consistency evaluation for generic drugs.子公司浙江天元生物药业的四价流感病毒裂解疫苗临床试验申请获国家药监局受理；子公司盐酸克林霉素胶囊通过仿制药一致性评价。
2026-05-08Controlling subsidiary Zhejiang Tianyuan participates in the national major S&T project 'Multifunctional Antibody Preventive HIV Vaccine R&D', responsible for vaccine production and Phase I clinical application (project period 2026/3-2031/2).控股子公司浙江天元参与国家科技重大专项'多功能抗体预防性艾滋病疫苗研发'，负责疫苗生产和I期临床申报（项目执行期2026年3月至2031年2月）。
2026-05-14Controlling subsidiaries Zhejiang Huapai Bio and Zhejiang Tianyuan Bio sign a cooperation agreement with Hefei Keyinuo Bio and Nanjing Keyinuo Bio on the licensing and commercialization of the human seasonal broad-spectrum influenza vaccine project (KYN003 pipeline and related technical know-how).控股子公司浙江华派生物、浙江天元生物与合肥科医诺生物、南京科医诺生物签署人用季节性广谱流感疫苗项目知识产权授权及商业化合作协议（KYN003管线及相关技术秘密）。
Subsidiary equity restructuring & transfers子公司股权重组与转让
18 · 2025-01-08 → 2026-06-08
▾
Multiple equity transfers at zero or nominal consideration to individuals, maintaining Buchang's controlling stake.多次以零元或名义对价向个人转让股权，保持步长控股地位。
2025-01-08Adjusted equity transfer plan for subsidiary Jinan Buchang Shengyuan Medical Devices: 1% stake transfer changed from Xing Jie to Diao Hailong.调整控股子公司济南步长晟源医疗器械股权转让方案，訾立宾拟转让的1%股权受让方由邢杰变更为刁海龙。
2025-01-16Adjusted shareholder structure for proposed subsidiary Shandong Buchang Guanyou Medical Devices: Buchang Pharmaceutical holds 90% (CNY 4.5 million), Xie Jihui 4%, Yu Haiming and Liu An'an 3% each.调整拟设子公司山东步长冠优医疗器械有限公司股权结构：步长制药出资450万元持股90%，谢继辉持股4%，于海铭和刘安安各持股3%。
2025-05-20Planned to transfer 1% equity in each of 9 controlled subsidiaries (e.g., Ningbo Buchang Trade, Shandong Buchang Cosmetic) to Xie Jihui for a total consideration of RMB 50,000 (5,000 for one, 0 for eight).拟将9家控股子公司（如宁波步长贸易、山东步长药妆等）各1%股权转让给谢继辉，总对价5万元（其中一家5万元，八家0元）。
2025-05-26Board approved waiving the preemptive right for a 1% equity transfer in controlled subsidiary Shandong Buchang Zhongxinkang from Wei Lihua to Gao Jinliang for RMB 25,000; Buchang's stake remains 90%.董事会同意放弃控股子公司山东步长众鑫康1%股权（韦礼华转让给高金亮，对价2.5万元）的优先受让权，步长持股比例保持90%。
2025-07-01Completed transfer of 1% equity in subsidiary Buchang Zhongxinkang from Wei Lihua to Gao Jinliang for 25,000 yuan; Buchang Pharma waived preemptive right, maintaining 90% stake.完成控股子公司步长众鑫康1%股权转让，原股东韦礼华以2.5万元转让给高金亮，步长制药放弃优先受让权，持股比例仍为90%。
2025-07-09Buchang Pharma waived preemptive rights on 0.50% and 1.00% unpaid equity transfers in subsidiary Buchang Zhenze, and on 2.00% and 1.00% transfers in subsidiary Buchang Guanyou; its stake in both remained at 90%.步长制药放弃对控股子公司步长臻泽0.50%和1.00%未实缴股权转让的优先受让权，以及对步长冠优2.00%和1.00%股权转让的优先受让权；持股比例均保持90%。
2025-07-12Completed transfer of 1% equity each in 7 health-industry subsidiaries (including Shandong Buchang Yaozhuang, Buchang Dingsheng, etc.) to Xie Jihui at 0 yuan; Buchang Pharma retained over 90% stake in each.完成向谢继辉以0元转让7家大健康产业子公司（包括山东步长药妆、步长鼎晟等）各1%股权；步长制药持股比例均超过90%。
2025-08-07Company transferred 2% equity in Buchang Caigan to He Tao at RMB 0, and relinquished preemptive rights on other equity transfers, reducing its stake in Buchang Caigan from 93% to 90%.公司以0元将步长财淦2%股权转让给何涛，并放弃其他股权转让的优先受让权，持股比例由93%降至90%。
2025-08-16Company signed equity transfer agreements for Buchang Caigan, Buchang Zhenze, and Buchang Guanyou, transferring unregistered equity at RMB 0 to individuals, with Buchang's controlling stake remaining at 90% in each.公司签署步长财淦、步长臻泽、步长冠优的股权转让协议，以0元转让未实缴股权给个人，步长在各子公司中的控股比例保持90%。
2025-09-05Buchang Pharma agreed to transfer 0.50% equity in Buchang Chuanfang to He Tao for 6,875 yuan, and waived preemptive rights on other transfers, reducing its stake to 92.5%.步长制药以0.6875万元将步长传方0.50%股权转让给何涛，并放弃其他转让优先受让权，持股降至92.5%。
2025-09-05Buchang Pharma's subsidiary Buchang Dingsheng saw equity transfers: Zhao Lu sold 3.00% to Xie Jihui for 42,366 yuan, Guo Yubiao sold 1.00% to Xie Jihui for 14,122 yuan, Cai Yunfei sold 1.00% to He Tao for 14,122 yuan; Buchang waived preemptive rights, retaining 94.00%.步长制药子公司步长鼎晟股权转让：赵路以4.2366万元将3.00%转让给谢继辉，郭玉彪以1.4122万元将1.00%转让给谢继辉，蔡云飞以1.4122万元将1.00%转让给何涛；步长放弃优先受让权，持股94.00%。
2025-09-05Buchang Pharma acquired 1.50% unpaid equity in Buchang Cosmetics from Zhao Lu for 0 yuan, increasing stake to 94.50%; Zhao Lu transferred remaining 1.50% to Xie Jihui and Wang Qi at 0 yuan, with Buchang waiving preemptive rights.步长制药以0元受让赵路持有的步长药妆1.50%未实缴股权，持股增至94.50%；赵路将剩余1.50%以0元转让给谢继辉和王奇，步长放弃优先受让权。
2025-10-18Acquired 1.50% unregistered equity in subsidiary Shandong Buchang Cosmetics Biotechnology at RMB 0, raising stake from 93% to 94.50%; waived preemptive rights on other transfers.以0元受让控股子公司山东步长药妆生物科技1.50%未实缴股权，持股比例由93%升至94.50%；放弃其他股权转让的优先受让权。
2026-03-12Controlling subsidiary Shandong Buchang Guanyou Medical Devices' minority shareholder Liu An'an transfers 1% unpaid equity to He Tao at zero price; Buchang's 90% stake unchanged.控股子公司山东步长冠优医疗器械少数股东刘安安以0元转让1%未实缴股权给何涛，步长持股90%不变。
2026-04-07Board approved transfer of 1% equity in subsidiary Shandong Buchang Changyan Biotechnology from departing shareholder Ding Li to Wang Minxi for 13,686 yuan, based on net assets.董事会批准控股子公司山东步长畅妍生物科技有限公司1%股权由离职股东丁莉以1.3686万元转让给王敏熹。
2026-05-14Buchang transfers 2% equity in Buchang Dingsheng Pharmaceutical to Zhang Jiancang and 2% to Zhang Yubo at 28,142 yuan each; Xie Jihui transfers 1% to Yang Hongjun at 14,071 yuan; Buchang waives pre-emptive rights, retaining 90% stake.步长制药将所持步长鼎晟药业2%股权以2.8142万元转让给张建苍、2%以2.8142万元转让给张雨博；谢继辉将1%以1.4071万元转让给杨宏军，公司放弃优先受让权，仍持有90%股权。
2026-05-29Buchang transfers its 1% stake in Jinan Buchang Yingxi Trading to Cheng Shiqi at 1,828 yuan and waives pre-emptive rights; formal agreement signed.步长制药将其所持济南步长瀛玺商贸1%股权以1,828元转让给程诗淇并放弃优先受让权，正式签署协议。
2026-06-08Subsidiary Jinan Buchang Chicheng: shareholder Fang Kerui transfers 1% equity to Zeng Lingminghui and 1% to He Yu, each at 5,942 yuan; Buchang maintains 91% stake.控股子公司济南步长驰骋股东房克瑞分别向曾令明慧、何宇转让1%股权（各5942元），步长持股91%不变。
Adalimumab injection (阿达木单抗注射液) development阿达木单抗注射液开发
4 · 2025-03-07 → 2026-06-08
▾
Marketing authorization application accepted; entrusted production approved; Vietnam distribution deal signed.上市申请获受理；委托生产获批；签署越南分销协议。
2025-03-07Subsidiary Luzhou Buchang receives approval to change Drug Production License, entrusting Beijing Zhaoyan Biotechnology to produce adalimumab injection; classification code changed from As to AsBs.控股子公司泸州步长获准变更《药品生产许可证》，委托北京昭衍生物技术有限公司生产阿达木单抗注射液，分类码由As变更为AsBs。
2025-06-10Controlling subsidiary Luzhou Buchang's marketing authorization application for Adalimumab injection (40mg/0.8mL) was accepted by NMPA; R&D cost ~181 million yuan as of May 31, 2025.控股子公司泸州步长的阿达木单抗注射液（40mg/0.8mL）药品注册上市许可申请获国家药监局受理；截至2025年5月31日研发投入约1.81亿元。
2025-09-08Buchang Pharma's subsidiary Sichuan Luzhou Buchang Bio's adalimumab injection registration application was accepted by the NMPA.步长制药控股子公司四川泸州步长生物的“阿达木单抗注射液”注册申请获国家药监局受理。
2026-06-08Controlling subsidiary Luzhou Buchang signs exclusive distribution, marketing service and agency agreement with Vietnam's MKT and Zao'an International for Adalimumab Injection in Vietnam, valid until 2036-06-30.控股子公司泸州步长与越南MKT及早安国际签署独家经销、营销服务和代理协议，授权MKT在越南独家营销和经销阿达木单抗注射液，协议至2036年6月30日。
Share cancellation & capital reduction股份注销与减资
5 · 2025-05-26 → 2025-09-04
▾
Cancelled repurchased shares to reduce registered capital, approved by shareholder meetings.注销回购股份以减少注册资本，经股东大会批准。
2025-05-26Board approved changing the use of 6,620,630 repurchased shares from employee stock plan/equity incentive to capital reduction and cancellation, reducing total share capital to 1,054,568,442 shares.董事会同意将6,620,630股回购股份用途由员工持股计划/股权激励变更为减少注册资本并注销，总股本缩减至1,054,568,442股。
2025-06-26Annual general meeting approved 21 proposals including 2024 profit distribution (no cash dividend), cancellation of 44.85 million repurchased shares (4.06% of total), 2025 interim dividend plan, up to 5.04 billion yuan financial assistance to subsidiaries, and 6.92 billion yuan new financing and guarantee limits.年度股东会审议通过21项议案，包括2024年度不进行现金分红、注销4485万股回购股份（占总股本4.06%）、2025年中期分红安排、向子公司提供不超过50.4亿元财务资助及新增69.2亿元融资担保额度。
2025-06-27Company announced cancellation of 51,474,203 repurchased shares from two buyback programs (total cost over 810 million yuan), reducing registered capital from 1.106 billion to 1.055 billion shares.公司宣布注销两期回购的合计5147.42万股股份（总耗资超8.1亿元），注册资本由11.06亿股减至10.55亿股。
2025-08-12Completed cancellation of 51,474,203 repurchased shares (44,853,573 + 6,620,630) to reduce registered capital, with the cancellation effective August 12, 2025.完成注销51,474,203股回购股份（44,853,573股+6,620,630股）以减少注册资本，注销于2025年8月12日生效。
2025-09-04Buchang Pharma announced cancellation of 51.4742 million repurchased shares (4.65% of total shares), reducing total share capital to about 1.055 billion shares, as part of its 2025 'quality improvement and efficiency return' plan.步长制药宣布注销此前回购的5147.42万股股份（占总股本4.65%），总股本降至约10.55亿股，作为2025年“提质增效重回报”行动方案的一部分。
Luzhou Buchang Biopharmaceutical GMP & production license泸州步长生物制药GMP与生产许可
4 · 2025-05-27 → 2025-08-01
▾
Obtained GMP certificates for Epoetin alfa injection; expanded production license for therapeutic biological products.获得依帕司他α注射液GMP证书；扩大治疗用生物制品生产许可范围。
2025-05-27Controlling subsidiary Luzhou Buchang obtained Drug GMP Compliance Inspection Certificate for injection Epoetin alfa (Class 1 new biologic, for CKD anemia), with annual design capacity of 2.36 million vials.控股子公司泸州步长获得药品GMP符合性检查告知书，涉及治疗用生物制品Ⅰ类新药注射用艾帕依泊汀α（用于慢性肾病贫血），设计年产能236万支。
2025-06-03Controlling subsidiary Luzhou Buchang obtained GMP compliance certificate for biological product (Epoetin alfa injection), covering production lines 02Y and 02C.控股子公司泸州步长获得治疗用生物制品（注射用艾帕依泊汀α）的药品GMP符合性检查告知书，涉及二车间（生产线02Y）和三车间（生产线02C）。
2025-07-31Subsidiary Sichuan Luzhou Buchang Bio-pharmaceutical obtained approval from Sichuan Medical Products Administration to expand Drug Manufacturing License scope to include therapeutic biological products (injectable recombinant anti-VEGFR2 fully human monoclonal antibody) for registration application use only.控股子公司四川泸州步长生物制药获得四川省药监局许可，增加《药品生产许可证》生产范围：治疗用生物制品（注射用重组抗VEGFR2全人单克隆抗体），仅限注册申报使用。
2025-08-01Controlled subsidiary Luzhou Buchang obtained approval from Sichuan Medical Products Administration to add production scope for 'injectable recombinant anti-VEGFR2 fully human monoclonal antibody (therapeutic biological product)', limited to registration application use.控股子公司泸州步长获得四川省药监局批准，新增‘注射用重组抗VEGFR2全人单克隆抗体（治疗用生物制品）’生产范围，仅限于注册申报使用。
Danhong Injection (丹红注射液) & Xuanfei Baidu Granules (宣肺败毒颗粒) national医保 renewal丹红注射液与宣肺败毒颗粒国家医保续约
1 · 2025-12-08
▾
Key products Danhong Injection and Xuanfei Baidu Granules renewed in National Medical Insurance catalog.核心产品丹红注射液和宣肺败毒颗粒成功续约国家医保目录。
2025-12-08Products Xuanfei Baidu Granules (exclusive) and Danhong Injection successfully renewed in the 2025 National Medical Insurance Catalog, effective 2026-01-01 to 2027-12-31. Xuanfei Baidu Granules had 2025 Q1-Q3 sales of RMB 124M (1.46% of revenue); Danhong Injection had sales of RMB 1.402B (16.59% of revenue).宣肺败毒颗粒（独家品种）和丹红注射液成功续约纳入《国家医保目录（2025年）》，有效期2026年1月1日至2027年12月31日。宣肺败毒颗粒2025年前三季度销售额1.24亿元（占营收1.46%）；丹红注射液销售额14.02亿元（占营收16.59%）。
Overseas drug registrations (Indonesia, Malaysia, Hong Kong)海外药品注册（印尼、马来西亚、香港）
2 · 2025-12-15 → 2026-04-08
▾
Multiple products registered or renewed in Indonesia, Malaysia, and Hong Kong.多个产品在印尼、马来西亚和香港注册或续期。
2025-12-15Products Xuanfei Baidu Granules and Tongbianling Capsules obtained drug registration certificates from the Indonesian Ministry of Health. Additionally, 8 products including Buchang Wenxin Granules, Kekou Oral Liquid, and Yangzheng Mixture successfully renewed registration in Indonesia. Buchang now has over 20 products marketed in Indonesia.宣肺败毒颗粒和通便灵胶囊获得印度尼西亚卫生部药品注册证书。此外，步长稳心颗粒、咳露口服液、养正合剂等8个产品在印尼成功续注册。步长制药目前在印尼共有20多个产品上市。
2026-04-08Exclusive product Yangzheng Heji (Yangzheng Mixture) received Malaysian Drug Control Authority registration as a traditional Chinese medicine, valid from 2026-04-02 to 2031-04-02. Product 2024 sales: 47.09 million yuan; 2025 Jan-Sep sales: 39.27 million yuan.独家品种养正合剂获得马来西亚药物管制局传统中药注册证明（有效期2026-04-02至2031-04-02）。2024年销售收入4709.47万元，2025年1-9月销售收入3926.56万元。
